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Hypertension is associated with end organ damage (EOD). Since EOD is a risk factor for 
cardio- and cerebrovascular complications, it is a major requirement for these to be 
detected, prevented and treated. A total of 147 consecutive patients with newly-diagnosed 
essential hypertension and attending the outpatient clinic were included in this study based 
on a set of inclusion and exclusion criteria  (patients with co-morbid illnesses were 
excluded from the investigation). Among them, 86% (70 male (M) and 56 female (F)) had 
one or more EODs, an observation which was very close to statistically significance 
(P=0.054). The presence of one or more EODs in newly-detected hypertension indicates 
widespread vascular damage which carries the high risk for cardio- and cerebrovascular 
morbidity and mortality.  
 
Although thyroid dysfunctions exert significant effects on blood pressure (BP), published 
literature available has revealed contradictory data. Objective of our study was to explore 
the inter-relationships between selected thyroid dysfunctional status (hyper and 
hypothyroid) and established biomarkers [thyroid stimulating hormone (TSH) and 
thyroxine (T4)]; and BP components [specifically Systolic BP (SBP), Diastolic BP (DBP), 
and Mean Arterial Pressure (MAP), and uniquely SBP:DBP ratio]. We followed rigid 
criteria in order to select adults with hyperthyroidism (n=71) and hypothyroidism (n=300), 
together with healthy age-matched controls (n =300), and applied a series of statistical 
analyses on the datasets acquired. We have observed thyroid dysfunctional status is 
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associated with elevated BP, and increasing BP is positively-correlated with elevated 
serum thyroid biomarkers, hyper and hypothyroid disorders should be recognized and 
treated early in order to avoid  critical hazards presented by high BP.  
 
Also, we have studied awareness among public and physicians in managing hypertension. 
Overall, the levels of knowledge and awareness among both groups are sub-optimal. Hence 
there is an urgent need for empowerment among both groups to enhance awareness and to 
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CHAPTER 1. INTRODUCTION 
Worldwide, hypertension is the leading risk factor for both morbidity and mortality (1), 
and represents the attributable burden of disease in South Asia(2). According to the World 
Health Organization (WHO) Global Health Report 2009, hypertension is the leading cause 
of mortality (responsible for 13% of deaths globally). Followed by hypertension, tobacco 
use (9%), diabetes (6%), physical inactivity (6%) and excess weight/obesity (5%) are also 
responsible for this mortality risk. Indeed, the 2004 WHO report stated that  hypertension 
is one of the important causes for death worldwide (3). Moreover, such conditions affect all 
groups regardless of their socio-economic status, which was found to be similar in our 
previous study(4).  
 
By definition, hypertension is defined as a blood pressure index of greater than 135/85 
mmHg for automated office/home/ambulatory day-time blood pressure readings, or more 
than 130/80 mmHg in for 24 hour ambulatory blood pressure readings(5). Patients are 
considered to be hypertensive even in the first visit if they present with hypertensive 
urgency or emergency(5). The average blood pressure >160/100  mmHg across 3 visits or 
average values >140/90 mmHg across 5 visits is also acknowledged  to indicate 
hypertension(5).  Hypertensive urgencies and emergencies are defined as diastolic blood 
pressure values ≥ 130 mmHg, or severe blood pressure with end organ damage(5).  
  
The prevalence of hypertension in  the Indian population is increasing, and notably it was 
25% according to a previous report (6). Different studies showed the rise in prevalence of 
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hypertension, however there were some differences noted in the prevalence rate from 
multiple reports. In the 2005 worldwide analysis of data available for the global burden of 
hypertension, the prevalence of hypertension amongst Indian men and women were 20.6% 
and 20.9%, respectively(7). These rates amongst Indian men and women are expected to go 
up to 22.9 and 23.6 % by 2025, respectively (7). The prevalence amongst urban and rural 
populations were 25 and 10% respectively (8-11). There was a notable difference in the 
prevalence and awareness of hypertension amongst the rural and urban Indian populations, 
and this is depicted in  Figure 1.1 (12). From the WHO report of 2008, the prevalence of 
hypertension amongst Indians was 32.5% (33.2% in men and 31.7% in women)(13). A 
multi-centre study from India showed that only about 25% of the patients had their blood 
pressure adequately controlled (14). Ibrahim etal., observed a notable difference in the 
prevalence, treatment, control and awareness of hypertension between people of developed 













Figure 1.1. Overall pooled estimates for the prevalence of hypertension in India 
 
Legend: Location-wise (rural and urban) and region-wise (north, east, west and south). P 
values obtained for overall rural and urban differences are: for hypertension prevalence in 
India (0.05*), for hypertension prevalence in East India (0.98), for hypertension prevalence 
in Northern India (0.07), for hypertension prevalence in Southern India (0.62), and for 
hypertension prevalence in West India (0.05*). CI – confidence interval, *statistically 
significant. Figure reproduced from Anchala etal., (12). P values for overall rural and urban 
population differences for awareness, treatment and under control for hypertension were 








Figure 1.2. Differences in the measures of hypertension between men and women in 
developing and developed countries.  
 











Table 1.1. Changes in the prevalence of hypertension in following countries over time 
Countries Year Prevalence (%) Year Prevalence (%) 
India 1988 6.6 2003 36.4 
China 1992-94 22.7 1998 24 
Tanzania 1987 26.3 1998 39.9 
Turkey 2003 28.9 2007 31.7 
Sub-saharan 
Africa 
1998 54 2003 78 
Legend: % - percentage, Table is adapted from Ibrahim et. al., (15).  
 
Data for the above table 1.1 is calculated for adults aged more than or equal to 55 years, 
and hypertension is defined as blood pressure > 160/95 mm Hg. Hence, Table 1.1 indicates 
that there was a rapid change in the prevalence of hypertension from 1988 to 2003 (it is 
almost 6 times increased over 15 years)(15). Moreover, this figure represents an 
underestimate of the abundance of hypertensive patients since the dataset collected 
included only blood pressure values > 160/90 mmHg as those with hypertension. In a 
recent hypertension study performed within the Indian population by Gupta et. al., it was 
shown that 55.3% of the population were aware of hypertension (16). Also, treatments 
available  and the adequate control of blood pressure amongst hypertensive populations 




1.1.Rationale and literature review 
1.1.A. End organ damage in hypertension 
Hypertension is difficult to diagnose since it is asymptomatic, and blood pressure 
represents a dynamic measure with inherent minute-to-minute variability; moreover,  there 
is currently a widespread application of erroneous techniques leading to inaccurate 
measurements (17). In ‘masked’ hypertension, patients have normal blood pressure in the 
clinician’s office, but high blood pressure during daily life, and these are of a high risk for 
cardiovascular events (18). Hence, 24-hour ambulatory blood pressure measurements offer 
an improved role for the management of hypertension, including the prediction of 
cardiovascular events (19). Furthermore, awareness, treatment and control of hypertension, 
and also techniques available for the measurement of blood pressure amongst health-care 
professionals remain sub-optimal (20, 21).  Hence, hypertension acts as ‘silent’ killer for 
many years prior to the time when overt end-organ damage (EOD) is clinically apparent. 
Most of the patients with essential hypertension are unaware of their disease status, and 
hence a large number of these subjects have EOD on their first arrival at hospital (22). 
 
The manifestations of EOD include micro and macrovasculature pathology such as stroke, 
coronary artery disease (CAD)/structural cardiac problems, retinopathy, 
proteinuria/chronic kidney disease (CKD), and atherosclerotic changes anywhere in the 
body system. The cost is greater, efficacy and prognosis are lower, for the management of 
blood pressure in patients with EOD (23). Hence, the early detection and treatment of EOD 
determines the cardiovascular prognosis in hypertensive patients, and can retard or prevent 
! 21!
further damage (24). A large body of evidence has suggested that microalbuminuria in 
hypertensives is a predictor of organ damage and cardiovascular events (25). In our 
previous report, we noted that increased aortic stiffness, left ventricular hypertrophy (LVH) 
and increased left ventricular (LV) mass were dependent on the duration and severity of 
hypertension (26).  LVH is an independent risk factor for cardiovascular morbidity and 
mortality in the general population and amongst hypertensives (27). In addition, large 
epidemiological studies have shown associations between retinopathy and systemic 
diseases such as hypertension, cardiovascular diseases, diabetes and stroke (28). Also, a 
relationship between hypertensive retinopathy and blood pressure values (current and past) 
has been demonstrated (28). Therefore, hypertensive retinopathy, serves as a further sign of 
EOD and hence a predictor of cardiovascular risk (29). 
 
1.1.A1.Pathogenesis of end organ damage in patients with hypertension 
There are a multitude of factors involved in the pathogenesis of end organ damage in 
addition to pressure overload in hypertension (30, 31). Furthermore, these factors affected 
the end organs independent of severity of hypertension (30, 31). These factors include the 
renin-angiotensin- system (RAS), the sympathetic nervous system, and metabolic and 
inflammatory processes. Stimulation of RAS increases angiotensin levels, which promotes 
the left ventricle hypertrophy (LVH). Metabolic causes include obesity and high salt 
consumption, either through hormones or the RAS promotion of end organ damage in 
hypertensive patients. Hypertension causes endothelial dysfunction and causes the 
remodeling of both small and large arteries. This, in turn, reduces the elastic nature of 
vessels, increases stiffness and decreases distensibility. Moreover, stiffness in the aorta 
! 22!
increases the left ventricular overload and impedes the left ventricular function(26). 
Overall, this leads to plaque formation, stenosis and aneurysm in the vessel and thus cause 
vasculopathy. Table 1.2 provides a summary of end organ damage experienced in 
hypertension patients (31).  
Table 1.2. End organ damage in hypertension 
Organ End organ damage 
Heart • Left ventricular hypertrophy 
• Atrial fibrillation/arrhythmias 
• Coronary artery disease/microangiopathy 
• Congestive cardiac failure 
Blood vessels • Endothelial dysfunction 
• Remodelling of vessels 
• Generalised atherosclerosis 
• Aneurysm 
• Microangiopathy (retinopathy) 
Brain • Stroke  
• Lacunar infarction 
• Intra cerebral haemorrhage 
• Acute hypertensive encephalopathy 
Kidney • Microalbuminuria/proteinuria 




1.1.A2. Hypertensive heart disease 
Hypertension causes structural and functional pathologies in the heart (32), amongst which 
LVH is of much importance, and plays a central role in inducing different pathologies and 
complications in the heart (Figure 1.3) (31). LVH causes impaired left ventricular 
relaxation and thereby it causes delayed diastolic filling. In the late stage, the compliance 
of the left ventricle is reduced, with ensuing diastolic heart failure. Electrocardiography 
(ECG) will provide reliable clues regarding the diagnosis of LVH, and the commonly used 
criteria is Sokolow-Lyon index (33), which is shown in the Figure1.4. However, 
acquisition of an   echocardiogram serves as the diagnostic test for hypertensive heart 
disease, which assists with measurements of the dimensions of chambers, and also  
function of the heart. Left ventricular masses greater than 259 grams in men, and 166 
grams in women, are considered abnormal (23). LVH is considered to be present if the 












Figure.1.3. hypertensive heart disease – pathogenetic factors and clinical implications 







LVH causes myocardial infarction, heart failure, arrhythmia, embolic phenomena and 
sudden death (31).  However, a reduction in LV mass reduces the risk of cardiovascular 
events by more than 50% (34). Indeed, an LV mass change of more than 35 g between two 
different measurements is considered significant in view of  variability between the 
echocardiographic measurements made by observers (31, 34). ACE inhibitors and 
angiotensin receptor blockers are the primary choices in such cases, and these effectively 
prevent the ventricular remodeling and also the further complications or pathologies 
induced by LVH (31). Beta blockers are used in the settings of tachyarrythmia in order to 
control heart rate.  
 
1.1.A3. Hypertensive nephropathy 
Chronic renal failure is the most common manifestation of hypertensive nephropathy, 
which often develops after 15 to 20 years (31). The easiest and earliest ways to detect 
hypertensive nephropathy are microalbuminuria and estimated glomerular filtration rate 
calculation (EGFR) (35). Leoncini et. al., demonstrated a significant change in the 
estimation of cardiovascular risk assessment based on the renal parameters 
microalbuminuria and EGFR for hypertensive end organ damage (35). In view of its 
molecular size, albumin can be traced to glomeruli through different layers such as 
endothelium, basement membrane and podocytes that are associated with increased 
permeability. However, this process is not restricted to renal vasculature but is also 
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observed in other vascular systems. Hence, albuminuria is a predictor for chronic renal 
insufficiency and cardiovascular events.      
 
Microalbuminuria is a sensitive indicator for the early signs of nephropathy, and is also 
considered as a valuable tool in the diagnosis of coronary heart disease (36), which has 
been proved again in the HOPE study (37). Both the European Society of Cardiology and 
the European Society of Hypertension urged the clinical importance of screening for 
microalbuminuria in the 2007 hypertension guidelines (38). Also, these societies 
recommended the screening of microalbuminuria in the assessment of end organ damage 
and in all hypertensive patients because of its easy availability, detection and low price 
(38). In a study conducted amongst Singapore physicians, that the majority of doctors 
(about 88%) screen their patients for microalbuminuria (36).  
 
Aggressive management to control hypertension and prevent the further progression of 
renal failure is mandatory in order to prevent renal failure and cardiovascular implications. 
In the LIFE study, hypertensive patients with LVH who were treated and showed a 
reduction in albuminuria had fewer cardiovascular complications (39). Concurrent findings 
have been noted in the RENAAL study, which also included diabetic patients(40). The 
recommended target blood pressure in hypertensive nephropathy is less than 130/80 
mmHg; however, in the presence of proteinuria, it should be even lower (41). Numerous 
studies including large retrospective ones have confirmed the nephroprotective effects of 
ACE inhibitors/angiotensin receptor blockers and direct renin inhibitors (41, 42).  
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1.1.A4. Hypertensive retinopathy 
Hypertensive retinopathy is considered as a significant risk, and prognostic indicators for 
systemic mortality and morbidity (29). Hypertensive retinopathy is graded into four 
categories according to the standard and old criteria ‘Keith-Wagener-Barker’ classification 
(illustrated in Table 1.3) (43).  
 
Table.1.3. Keith-Wagener-Barker (KWB) classification of hypertensive retinopathy 
Grade Features  
Grade  I  Mild generalized retinal arteriolar narrowing 
Grade II Definite focal narrowing and arteriovenous (AV) 
nipping 
Grade III The above findings plus retinal haemorrhages, exudates 
and cotton wool spots 
Grade IV Severe grade III and papilloedema 
 
The older criterion has been modified according to strategies and patient’s approach 
towards the risk assessment of mortality and morbidities of cardiovascular diseases, and 
this is shown in Table 1.4(29). However, in this study, we have used the standard criteria, 





Table.1.4. Three Grades classification of Hypertensive Retinopathy and their Systemic 
associations(29).  
Grades of retinopathy Definition Systemic associations 
Mild Grade I + Grade II of KWB 
classification 
Weak associations with 
stroke and cardiovascular 
disease 
Moderate Grade III of KWB 
classification 
Strong associations with 
renal failure, stroke and 
cardiovascular disease 
Accelerated Grade IV of KWB Associated with increased 
mortality from any of 
systemic diseases 
 
There are many population studies which have provided the data on the prevalence of 
hypertensive retinopathy with associated signs/grades (29, 45-52); The prevalence varied 
from 3 to 14% of the adult population (29). Table 1.5 provides the prevalence of 
hypertensive retinopathy with signs from different population-based studies (Figure 





Table.1.5. Prevalence of hypertensive retinopathy associated signs from different 
populated-based studies  
 
Legend: +++ : Strong association (relative risk/odds ratio is > 2), ++: Moderate association 
(relative risk/odds ratio is 1.5 to 2), +: Weaker association (relative risk/odds ratio < 2). 
The above data was tabulated by Wong etal.,(29) from different population based studies 
and the table is adapted from Wong etal., (29). 
 
Figure.1.4. Fundoscopy revealing exudates, hemorrhage and papilloedema  
 
Legend: The figure copied from Porta etal., (53) 
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1.1.A5. Rationale for the study 
Medical societies dedicated to hypertension have focused not only on blood pressure for 
risk stratification, but also on other factors such as cardiovascular risk factors and the 
detection of EOD (24). Patients with grade I hypertension can be associated  a mild or 
significant risk, depending on what additional EOD is present, and further co-morbidities 
such as diabetes, dyslipidemia, etc. In our system, most of the patients visit clinicians only 
when the symptoms are distressing, a phenomenon which is unlikely in the case of 
uncomplicated hypertension. Also, most physicians do not routinely check blood pressure 
in their patients regardless of the purpose of the clinic visit. Many young adult patients 
admitted to hospitals with one or other form of end organ damage made clear the essential 
requirements for this study. To the best of our knowledge, there are no published reports on 
covert EOD in newly-detected essential rural hypertensives from the Southern Indian 
region.  
 
1.1.B. COMMON BUT IGNORED CAUSES FOR HYPERTENSION IN INDIA 
Snake bite envenomation is a common problem in India in view of its vast rural areas. 
Hypertension, including malignant and urgent cases, are notable in those which require 
urgent intravenous anti-hypertensive medication in order to control blood pressure to avoid 
further complications. However, such pathogenesis is not commonly considered by 





Thyroid disorders are common in India. Indeed, hypertension is predominant amongst 
Asian populations. Hypertension in thyroid disorders is known, but is also less commonly 
considered in all thyroid disorder patients, nor to  check for thyroid status in hypertensive 
cases, at least for resistant/malignant hypertension or hypertension with EOD, or patients 
with clinical signs or symptoms indicating thyroid dysfunction. Hence, we have included 
these studies in our research. Additionally, hypertensive patients with one or other forms of 
end organ damage on the background of thyroid dysfunction, and even with maximal anti- 
hypertensive therapy, blood pressure will not be adequately controlled unless the 
associated thyroid dysfunction is treated adequately. We have encountered few such 
patients while we were performing our evaluation of end organ damage in newly-detected 
hypertensives (however, they were excluded from the study in view of the exclusion 
criteria). These observations rendered our further study to investigate links between thyroid 
disorders and hypertension essential.   
 
1.1.C. Hypertension in snake bite 
Snake envenomation is a common medical emergency in India with an estimated mortality 
rate of 35,000-50,000 people per annum (54). Indeed, elapid snake envenomation has been 
recorded as a frequent occurrence in India, amongst which common (or ’Indian’) krait 
species (Bungarus caeruleus) is also included. The classic symptoms observed in krait bite 
(which is often described as painless) are early morning symptoms such as abdominal pain 
or cramps (55), together with progressive muscular paralysis which often commences with 
ptosis. In this work, I present three cases of elapid envenomation with severe hypertension  
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requiring intravenous anti-hypertensives. Interestingly, snake (krait) bite was unknown to 
all three individuals, but was brought to our attention after an elaborate history and the 
performance of a detailed physical examination. These cases are presented in order to 
create an awareness of such issues amongst those practicing under resource-limited 
environments in which snake bites are prevalent and frequently-encountered.  
 
1.1.D. Hypertension in thyroid disorders 
1.1.D1. Thyroid hormone metabolism 
Thyroid hormones such as triiodothyronine (T3) and tetraiodothyronine (T4) are produced 
in the thyroid gland in a ratio of 1:7. The synthesis of thyroid hormones is via an enzymatic 
process which involves thyroid gland, pituitary gland, liver, kidney and skeletal muscle, 
and secretion is primarily regulated by the thyroid stimulating hormone (TSH)(56, 57).  A 












Figure 1.5. Thyroid hormone synthesis  
 
Legend: Within the iodide cycle, ingested iodide is trapped in the thyroid, oxidised, and 
bound to tyrosine to form iodotyrosines in thyroglobulin (TG); coupling of iodotyrosyl 
residues forms T4 and T3. The hormones secreted by the gland is transported in serum 
(some T4 is deiodinated to T3). The hormone exerts its metabolic effect on the cell and is 
ultimately deiodinated; the iodide is then reused or excreted in the kidney. A second cycle 
goes on inside the thyroid gland, with deiodination of iodotyrosines generating iodide, 
some of which is reused without leaving the thyroid (57). The Figure 1.6 is reproduced 
from Miot etal., (57). 
 
Thyroid hormones exert a range of actions on physiological systems of the body, including 
cardiovascular physiology. Thyroid dysfunction is associated with increased mortality  
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from, or a high prevalence of, cardiovascular diseases (58); deviations from euthyroid 
status affect normal physiology. Other than the well known effect of atherosclerosis in 
hypothyroidism, and also the risk of atrial fibrillation in hyperthyroidism, thyroid 
hormones exert a major effect on the heart and blood vessels (59). Cardiac output is 
maintained by peripheral vasoconstriction, arteriolar dilatation, blood volume and venous 
capacitance in response to the metabolic needs of tissue (59). Venous return is determined 
by blood volume and venous capacitance. Arteriolar dilatation decreases peripheral 
vascular resistance which increases afterload and cardiac output. A flow law chart which 
includes hemodynamic parameters, and each parameter which is influenced by thyroid 
hormone, is depicted in the figure 1.7 (59). In addition, thyroid hormones influence the 
autonomic nervous system, renin angiotensin aldosterone system (RAAS), renal function 













1.1.D2. Effect on thyroid hormones on Cardiovascular Physiology 
Triiodothyronine (T3) is the major thyroid hormone which acts on the heart, and the effect 
of T3 in cardiac physiology is noted in Table 1.6 and Figure 1.8 (59, 60). Furthermore, 
Table 1.7 depicts changes in the cardiovascular function in thyroid disorders (60).  
 
Table 1.6. Action of T3 on the heart (59, 60). 
ACTION OF T3 ON HEART 
Increases the speed and force of systolic contraction 
Increases the speed of diastolic relaxation 
Decreases vascular resistance 
Increases coronary vascular tone 











Figure 1.6. Thyroid hormone on cardiovascular hemodynamics  
 
Legend: The figure is reproduced from Klein et. al.(61). T3 and T4 – Thyroid hormones,     











Table 1.7. Changes in Cardiovascular Function in Thyroid Disorders (60)  
Parameters Hyperthyroidism Hypothyroidism 
Heart rate Increased Decreased 
Ejection fraction Increased Decreased 
Cardiac output Increased Decreased 
Blood volume Increased Decreased 








Thyroid hormone action is generally mediated through the thyroid hormone receptors (TR), 
TR α (alpha) and TR β (beta)(59). The predominant receptor in the heart is TR α and T3 
binds to TR α in cardiac myocytes(59, 60, 62-64), which in turn promotes the number of 
processes including protein (titan) transition through phosphorylation or activation of 
phosphoinositol 3-kinase (PI3-K), protein kinase B and the mammalian target of rapamycin 
(MTOR)(65-68). These are modulated by decreases in protein kinase C, and corresponding 
increases in atrial natriuretic peptide (ANP)(67, 68). Moreover, these changes induce 
alterations in gene expression and thus initiates cardiac hypertrophy. Alterations in gene 
expression includes a positive effect exerted on the transcription of the myosin heavy chain  
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(MHC) α gene, and a negative effect on the MHC β gene(59, 60, 62-64). Thyroid 
hormones increase ATP (adenosine triphosphate) and gene expression of sarcoplasmic 
reticulum calcium ions (SRCa), together with a  decreased expression of the MHC β gene. 
Overall, thyroid hormone inhibits SRCa through activation of SRCa ATPase and ryanodine 
channel, and an inhibition of phosphorylation of phospholamban, a substance present in the 
SRCa pump for activation (69-71). In view of this, diastolic function of the heart is 
affected due to poor contractility from low calcium ion in cardiac myocytes (59). T3 also 
promotes β1 adrenergic receptors and inhibits TR α receptors, which in turn mediates the 
inotrophic and chronotrophic effects of the heart (60).  A summary of T3 action on the 















Figure 1.7. Thyroid hormone effects on the heart  
 
Legend: Figure reproduced from Grais etal.(59). T3 = triiodothyronine; TR = thyroid 
hormone receptors; cAMP = cyclic AMP, PKC = protein kinase C; PI3-K = 
phosphoinositol 3-kinase; Akt = protein kinase B; (p) mTOR = phosphorylation of 
mammalian target of rapamycin; (p)ERK = phosphorylation of extracellular-signal-
regulated kinases; SERCa2+= sarcoplasmic reticulum Ca2+; Na = sodium; K-ATPase = 
potassium adenosine triphosphatase; MHCα =myosin heavy chain alpha; MHCβ = myosin 








Figure 1.8. Site of action of T3 in cardiac myocytes  
 
Legend: (Figure reproduced from Klein etal. (60).  Ca – calcium, K – potassium, Na – 




1.1.D3. Action of Thyroid hormones on blood vessels 
Thyroid hormones reduce the vascular tone and remodel the vessels. Various actions and 
mechanisms through which the thyroid hormone T3 influences the blood vessels are 
tabulated in Table1.8.  
 
Table 1.8. Actions and mechanisms of thyroid hormone (T3) on the blood vessels 
Action Mechanism through which 
Relaxation of vascular smooth 
muscle(60) 
(i) reduces expression of angiotensin II type 
1 receptor(72) 
(ii) reduces the calcium ion production and 
sensitivity(72)  
(iii) reduces contractile response to 
angiotensin II(72) 
(iv) stimulates nitric oxide production via 
activation of protein kinase B and 
phosphoinositol 3-kinase(73) 
(v) decreases myosin light chain 
phosphorylation and phenylephrine(73) 
Promotes angiogenesis Remodelling of vessels and endothelial 
dysfunction (74) 
Increases the density of small arterioles Remodelling of vessels(74) 
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Whilst atrial fibrillation and atherosclerosis are commonly reported in thyroid disorders, 
thyroid dysfunction causes multiple pathologies in the heart as listed in Table 1.9.  
 
Table 1.9. Thyroid dysfunction and cardiovascular pathology 
Organ/system Pathology (pathogenesis) 
Heart Systolic and diastolic heart failure 
(downregulation of thyroid hormone 
receptor) (60, 74) 
Atherosclerosis (through multiple 
mechanisms such as effects on blood vessels, 
dyslipidemia, endothelial dysfunction and 
others as noted above)(59, 60) 
Tachy- and brady-arrhythmia, most common 
is atrial fibrillation (through receptor and 
hormonal pathways)(59, 60) 
Valvular disease (through chamber 
dimension changes and high flow)(60) 
Pericarditis, pericardial effusion (through 
inflammatory process and volume retention 
(59, 60, 75)) 
Vascular system Systolic and diastolic hypertension 




Biochemical definitions of hyperthyroidism include low plasma or serum TSH and high T4 
or T3 levels, or both. Etiologies include Graves disease, thyroid nodules, iatrogenic 
overdosage and autoimmune thyroiditis. The common symptoms include thin body weight 
in spite of excessive appetite, moist skin, feelings of warmth, intolerance to heat, loss of 
body hair, diarrhoea, palpitations, headache, in addition to nail changes. Early treatment 
with anti-thyroid medications is mandatory in order to prevent complications. Thyroid 
storm or crisis is a life-threatening complication of hyperthyroidism, usually precipitated 
by acute illness, stress or infection. Patients involved require urgent treatments with 
antithyroid medication including beta blockers (which converts the peripheral conversion 
of T4 to T3), and other supportive treatments. Complications of hyperthyroidism are listed 
in the Table 1.10(59, 60).  
 
Table 1.10. Complications of hyperthyroidism 
Systolic hypertension 
Increased LV mass 
Poor exercise tolerance 
Angina 
Tachyarrhythmia, the common one is atrial fibrillation 
Heart failure (high output failure) 
Heart valvular disease 
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1.1.D5. Sub-clinical hyperthyroidism (SCH) 
Patients presenting with low blood plasma/serum TSH but normal T3 and T4 levels are 
considered as having sub-clinical hyperthyroidism. Previous studies,  including the 
Rotterdam study(76) concluded that SCH carries a similar risk and complications as 
hyperthyroidism, and hence such patients require the regular monitoring of overt thyroid 
disease and associated complications(76-78).  The need for treatment for SCH depends on 
the level of TSH, the aetiology of SCH, and associated co-morbidities(59).  
 
1.1.D6. Hypothyroidism 
Hypothyroidism is defined by low levels of T3 and T4 with raised TSH (through inhibition 
of negative feedback hormone). The clinical manifestations include fatigue, change in 
voice, constipation, plus intolerance to cold and skin changes. Treatments for 
hypothyroidism include replacement with thyroid hormones; however, a slow and cautious 











Table 1.11. Complications of hypothyroidism 
Hypertension (diastolic and systolic) 
Brady arrhythmia, the common one is sinus bradycardia 
Heart failure (systolic and diastolic) 
Dyslipidemia 
Metabolic syndrome 
Atherosclerosis including coronary artery disease, angina 
Endocardial fibrosis 
Myxomatous valuvular changes 
Pericarditis and pericardial effusion 
 
1.1.D7. Sub-clinical hypothyroidism (SCHO) 
SCHO is defined as high blood plasma/serum TSH, coupled with normal levels of T3 and 
T4. Like SCH, SCHO carries the risk and complications similar to hypothyroidism. 
However, the treatment depends on the level of TSH, aetiology and co-existing illnesses 
(59, 60).  
 
1.1.D8. Rationale of the study 
Although the effect of deviations from euthyroid status on blood pressure (BP) is more 
marked (79, 80), the relationship between thyroid disorders and BP is not well recognised 
(81). Moreover, to date a series of contradictory relationships have been noted. Indeed, a 
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linear relationship between serum TSH levels and BP (both systolic and diastolic) was 
observed by Asvold et. al. (82, 83). However, no such associations were observed in two 
further studies (84, 85). Physiologically, BP is maintained via cardiac output (CO) and 
systemic vascular resistance (SVR), and hence BP is calculated using the CO x SVR 
formula. As discussed above, through multiple mechanisms thyroid hormones maintain 
heart rate, cardiac contractility and blood volume, and hence exert an important influence 
on BP. In addition, thyroid hormones regulate BP through the renin-angiotensin-
aldosterone system (RAAS), in which hyper and hypothyroidism induce opposite effects 
(81). Moreover, thyroid disease can cause endothelial dysfunction through reduced 
fibrinolytic activity and nitric oxide (NO) synthesis (58). At the molecular level, thyroid 
hormones play an important role in the gene expression of cardiac myocytes (61). 
Furthermore, hypothyroidism has been associated with one or other metabolic syndrome 
components such as hyperlipidemia, diabetes and obesity (86).  
 
In this investigation, I have explored inter-relationships between thyroid dysfunctional 
status, together with their associated biomarkers and a range of BP components 
[specifically systolic BP (SBP), diastolic BP (DBP), Mean Arterial Pressure (MAP), and 
uniquely SBP:DBP ratio] monitored in a very large number of healthy control, hypothyroid 







1.1.E. Knowledge, attitude, behaviour and practice (KABP) among the physicians 
towards blood pressure management 
In countries with limited resources, the diagnosis of hypertension (HTN) is made by using 
mercury sphygmomanometers in clinical practice. Many technical errors might occur 
related to the equipment used in practice, and this could influence blood pressure readings. 
Inaccurate and unreliable equipment can lead to erroneous diagnosis with serious 
consequences for the patient (87). The American Heart Association (AHA) (88) recognises 
three sources of error in the measurement of BP: observer bias, faulty equipment and 
failure to standardise the techniques of measurement. International studies confirm that 
teaching, training and knowledge regarding blood pressure measurements and management 
for health care professionals are sub-optimal (89) (90) (91). Also, these gaps in training are 
continuing in medical education, and amongst interns and practitioners (90), (92). Hence, 
we have performed a questionnaire study focused on hypertension amongst physicians who 
manage this critical condition.    
 
1.1.F. Awareness of hypertension amongst the general public 
As discussed above, cardiovascular disease is the leading cause for mortality worldwide 
(93-96), and hypertension is a leading independent risk factor for cardio-cerebro vascular 
disease (96). In previously published studies concerning hypertension with complications, 
many of the patients were not even aware of this condition, and many subjects were 
unaware of the complications of it (97). In a PatenT study conducted throughout the 
Turkish population with 1,804 hypertensive patients, 59.3% of the subjects were not even 
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aware of hypertension, and only 8.1% of the subjects had adequate control (97, 98).  
Hypertension awareness amongst the Indian population was significantly lower than the 
awareness for diabetes (12). There was also a significant difference between awareness 
amongst rural and urban populations (12, 98). A further study, which compared the 
awareness of hypertension amongst Indians living in Singapore and rural India, has 
demonstrated a significant awareness within this urban population (99). In a recent study 
from India, amongst 6,106 subjects, awareness regarding hypertension was observed in 
only 55.3% of those surveyed, and the number of hypertensive subjects with an adequate 
control of blood pressure was sub-optimal (16). This is the current status not only in India, 
but also elsewhere (100). Lack of awareness of hypertension leads to sub-optimal control 
of blood pressure, a process which leads to reversible or irreversible end organ damage (16, 
100, 101). Hence, there is urgent requirement to study the awareness of hypertension 













1.2. Objectives of the study 
Considering the increasing prevalence of hypertension and its associated complications 
amongst Indians and also worldwide, this study was focused on determining the prevalence 
of EOD sequel in newly detected essential hypertensives without any other associated 
conditions. Also, the pattern of these EODs and their inter-relationships with age, gender 
and hypertension have been analysed. Whilst recruiting the patients for this study, I came 
across many with an inadequate control of blood pressure. Amongst them, more than 40% 
of patients have secondary causes of hypertension, and the most common cause 
encountered was thyroid disorders. Moreover, such patients were resistant to anti-
hypertensive drugs without their dysthyroid status being corrected. However, these patients 
were excluded from this study (status of EOD in newly detected essential hypertensives) in 
view of co-morbid illness as one of the study’s exclusion criteria.  
 
Common but simply ignored causes of hypertension in India include thyroid disorders and 
snake envenomation. In this study, I have presented cases of elapid envenomation 
experiencing severe hypertension. Furthermore, the primary objectives to explore inter-
relationships between thyroid dysfunctional status, together with their associated 
biomarkers and also a range of BP components [specifically systolic BP (SBP), diastolic 
BP (DBP), Mean Arterial Pressure (MAP), and uniquely SBP:DBP ratio] in a very large 
number of healthy control (euthyroid), hypothyroid and hyperthyroid patients have also 




For any diseases, physicians’ knowledge and patient awareness about the particular disease 
are mandatory measures for the disease identification, treatment, control and prevention. 
There are a very large number of reports available (published elsewhere) which have 
revealed that such measures for patients with hypertension are lacking. Additionally, press 
reports and lay media pronounce more information concerning diabetes rather than 
hypertension. Hence, in this study I have included a measure to study the knowledge, 
attitude, behavior and practice of blood pressure management amongst physicians in India, 



























CHAPTER 2. Status of end organ damage in newly detected hypertensives 
2.1.Methodology 
This study was performed at the tertiary care hospital, India after the receipt of informed 
consent from the recruited  patients and institutional ethical clearance according to Helsinki 
Declaration guidelines.  
 
Study population 
A total of one hundred and forty seven (n = 147) patients with newly-diagnosed essential 
hypertension, attending the outpatient clinic, were included for this present study based on 
a set of inclusion and exclusion criteria out of 450 patients consecutively seen, (patients 
with co-morbid illnesses were excluded from the study). The exclusion of other patients is 
given in the patient flow chart, (Figure 2.1). All cases were subjected to a complete history 
and physical examination with routine blood investigations. In addition, fundus 
examinations, 24-hour urine samples, electrocardiograms (EKG/ECG) and 





























































The blood pressure was taken as the mean of 3 readings in a relaxed and comfortable arm 
mode, and was based on standardised measures. All the cases in our study did not have any 
secondary causes of hypertension. Hypertension was defined and staged according to the 
seventh report of the Joint National Committee (JNC VII report) (102).  
 
Retinopathy 
Retinal examinations were performed in a dark room after instilling mydriatic agents, and 
were evaluated by a skilled ophthalmologist who had no prior information regarding the 




Urinary albumin levels were measured in 24-hr. urine collections after excluding urinary 
tract infection as an interferent. Microalbuminuria was defined as urinary excretion of 30- 
300 mg of protein per day (103). In order to limit false-positive results, all patients were 
advised to avoid heavy physical exercise during the 24-hour collection period.  
 
Electrocardiogram(EKG) 
EKGs was taken in all patients in order to assess the evidence of LVH. The Sokolow-Lyon 





2-D and M-mode Echo was performed on each patient in supine position to assess the LV 
function and morphology according to the American Society of Echocardiography 
Guidelines. LV masses greater than 259 grams in men and 166 grams in women was 
considered abnormal (23). LVH was considered to be present if the relative wall thickness 
was greater than 0.43 and/or LV mass is increased (23).    
 
Diastolic dysfunction  
Diastolic dysfunction was assessed using mitral E/A, deceleration time and iso-volumetric 
relaxation time (IVRT). The values of mitral E/A less than 1, deceleration times of greater 




An ejection fraction of 50-80 % was considered within normal limits. Values less than this 
were considered as systolic dysfunction (105).  
 
Statistical analysis 
Baseline characteristics of study patients were expressed as means ± standard deviations. 
Student’s t test was performed to determine the significance of mean differences observed 
between dependent variables, and ANOVA was used for those between independent 
variables. Moreover, the Chi-squared test was used to investigate the associations between  
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multiple variables, and associations between multiple variables such as systolic 
hypertension, diastolic hypertension, retinopathy microalbuminuria, LV mass, mean 
arterial pressure (MAP) and mitral E/A were explored using multiple logistic regression. A 
p value of ≤ 0.05 was considered as statistically significant. Statistical analysis was 
performed using the STATPAGES program (106).  
 
2.2.Results 
Demographic and clinical characteristics 
Amongst the 147 selected cases, there were 79 males (M) and 68 females (F). Their mean 
and median ages were 55 ± (standard deviation (SD) = 9.90) and 54 years respectively; 24 
patients were less than 45, 94 were between 45 and 64, and the remainder were more than 
or equivalent to 65 years of age. The distribution of systolic, diastolic and mean arterial 
pressures amongst them is depicted in Table 2.1. Within subject groups, 37 and 110 
patients were categorized under JNC class I and II criteria, respectively. Amongst subject 
groups, 126 (86%) of patients (70 M and 56 F) had one or other EODs, an observation 









Table 2.1:  Mean ± SD blood pressure values amongst subjects in the three age-group 
cohorts 
 Age group (in years) 
Male (n = 79) Female (n = 68) 
BP < 45 45-64 ≥ 65 < 45 45-64 ≥ 65 
SBP 152±14 166±16 163±13 167±13 166±16 176±15 
DBP 100±8 97±11 88±11 104±18 105±15 98±16 
MAP 86±15 102±16 104±15 98±12 96±15 111±14 
Abbreviations: SD = Standard deviation; BP = Blood pressure; SBP = Systolic blood 




Out of 147 patients, 51 (35%) had microalbuminuria. With reference to age group, 
microalbuminuria was noted amongst 8 (4M & 4F), 32 (13M & 19F) and 11 (8M & 3F) 
cases in the age groups of less than 45, 45 - 64, and 65 and above years of age respectively. 
There was no association between microalbuminuria, and age or gender.  Further analysis 
with Student’s t-test revealed that there was no correlation of microalbuminuria with 
systolic and diastolic blood pressures, nor the mean arterial pressure. 
  
Retinopathy 
Amongst the subject groups, 102 (69%) had retinopathy and its association with 
hypertension was highly significant (p=0.01). The involvement of retinopathy amongst 
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subject groups, with special reference to age and gender, is shown in Table 2.2. However, 
there was no significant association between retinopathy and gender or the age groups less 
than 45, and 45-64 yrs. However, there was a correlation between old age (≥ 65 yrs) and 
retinopathy (as expected). None of the patients had grade IV retinopathy.  
 
Table 2.2:  Relationship of retinopathy to age and gender 
Retinopathy 
Grade 
Age Group (in years) 
< 45 (n=24) 45-64 (n=94) ≥65 (n=29) 
Male Female Male Female Male Female 
0 3  
 


























8 3 38 32 12 9 
Total with 
HR  
11 70 21 
        Abbreviations: n = Number of Subjects; HR = Hypertensive retinopathy 
 
 
Left Ventricular (LV) mass 
Increased LV mass was noted amongst 100 (68%) cases, and the mean values were 264.85 
(± 71.79) and 231.59 (± 74.86) grams amongst males and females, respectively. This 
difference was significant (p=0.007, t value=2.74) amongst males but was not found to be 






Patients recruited to the study with diastolic dysfunction had only a grade I status 
(relaxation abnormality). The mean and the median mitral E/A values were 1.091 ± 0.513 
and 0.91 respectively. Amongst the cases, diastolic dysfunction was observed in 53 males 
(67.1%) and 33 females (48.5%), and it was found to be independent of both age and 
gender.  
  
Association of multiple factors 
The distribution of cases according to gender with retinopathy and with or without 
microalbuminuria is shown in Table 2.3.  
 
Table 2.3: Gender classification of patients with retinal Involvement with and without 
microalbuminuria 
 
Microalbuminuria Retinal involvement (n=102) 
Grade 0 Grade I Grade II & III 
Male Female Male Female Male Female 
Absent 18 22 31 14 5 6 
Present 3 2 8 8 14 16 
Total with MA 5 16 30 
Abbreviations: n = number; MA = Microalbuminuria. 
 
 
Statistical analysis with ANOVA revealed that there were significant differences between 
gender, retinopathy and microalbuminuria (p = 0.0001, ANOVA p = 0.0002). Also, 




diastolic dysfunction (p = 0.014). The distribution of LV mass and retinopathy with 
reference to gender is illustrated in Table 2.4.  
 
Table 2.4:  Retinopathy incidence according to grade, left ventricular mass and gender  
Ret. 
Grade 




























0 21 8 220.198 24 11 181.92 2.17 0.037* 





19 16 294.95 22 19 240.41 2.64 0.013** 
Abbreviations: n = Number of subjects; Ret. Grade = Retinopathy grade; Abnrl = 
Abnormal, LV mass = Left ventricular mass;  *and ** = statistically significant at the 5% 
and 2% levels respectively; ns = not significant. 
 
There was a significant association between increased LV mass and grade II and III 
retinopathy; however, this was not observed in grade I retinopathy. Furthermore, there was 
a correlation between stage II JNC and increased LV mass (p = 0.01), but not with stage I 
JNC (p = 0.63). The number of cases of left ventricular hypertrophy diagnosed by 
echocardiography was greater than those diagnosed by electrocardiogram, and the 
difference was statistically significant (p = 0.0003). We also found a strong association 
between LV mass and giddiness (p = 0015); however, there was no such association with 
other symptoms such as headache, chest discomfort and breathlessness. Statistical analysis 
using ANOVA found that diastolic dysfunction (mitral E/A) was significantly correlated 
with hypertensive retinopathy (p = 0.00005). A Chi-square test performed with IVRT and  
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deceleration time against retinal changes found highly significant p values of 0.0001 and 
0.00025 respectively. A correlation matrix was computed from the major variables 
involved in the study and this is shown in Table 2.5. Microalbuminuria was found not to be 
dependent on blood pressure levels, but it was positively correlated with retinopathy, LVH 
and diastolic dysfunction.  There was, however, a positive correlation between retinal 
changes and systolic blood pressure, but not with diastolic blood or mean arterial pressures. 
LV mass was associated with microalbuminuria and diastolic dysfunction, but not with 
blood pressure. LV mass had a strong positive relationship with diastolic dysfunction and 

















Table 2.5: Pearson correlation coefficients (r values) for relationships between the major 
Variables involved in the study 
 
2.3. Discussion 
WHO/International Society of Hypertension (ISH) guidelines have emphasised the concept 
that clinical decision making in hypertensive patients should not only include the 
measurement of blood pressure, but also rely on the monitoring systems that assess the risk 
of cardiovascular events (22). These measures include the presence or absence of 
concomitant risk factors, EOD and diabetes. In our study, microalbuminuria (35%), 
diastolic dysfunction (59%), increased left ventricle (LV) mass (68%) and retinopathy 







LV mass MAP 
Systolic 
HTN 
0.2892** 0.2284* 0.1143 0.0393 0.0222 0.8186** 
Diastolic 
HTN 
 0.1810 0.1215 0.0304 0.0661 0.3130** 
Retinopathy   0.3309** 0.2882** 0.3461** 0.1176 
Micro 
albuminuria 
   0.2898** 0.2734** 0.0405 
Diastolic 
dysfunction 
    0.5807** 0.0208 
LV mass      0.0176 
 
Abbreviations:  HR = Hypertensive retinopathy; LV mass = Left 
ventricular mass; MA  = Microalbuminuria;  HTN = Hypertension;   
MAP = Mean arterial pressure; Diast. Dysfun. = Diastolic 
dysfunction; * and ** = Significance of correlation coefficient (r) 
value (2-tailed test), p = 0 .01 and, 0.001 respectively. 
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hypertension indicates not only a high risk status, but also an indication to immediately 
institute an intensive management system for hypertension. Since most of the essential 
hypertensives had one or other EOD (9, 24), it is suggested that the screening of EOD 
should be made essential, at least in those above the age of 40 years with a linked 
retinopathy. Indeed, our observation that LV mass had strong association with 
microalbuminuria, diastolic dysfunction, grade II and III retinopathy confirms this. (109).    
 
Although ambulatory blood pressure monitoring (ABPM) in uncomplicated essential 
hypertension is of little value, except in some specific conditions, it provides further 
information regarding the pattern of blood pressure, and it is also more closely related to 
the provision of evidence for EOD. Indeed, at-home blood pressure monitors have better 
prognostic significance than clinical blood pressure recordings (110). However, the 
implementation of such measures in resource-limited settings is difficult in view of 
economical or policy demands. Also, the detection of EOD is influenced by many factors, 
including the accuracy of diagnostic tools and the availability of facilities and trained 
manpower. It has been recognized that the Echo monitoring system is more sensitive and 
specific than EKG measurements and chest X-ray evaluation for the detection of LVH 
(111), observations which were similar to those made here. Furthermore, the screening of 
microalbuminuria as an early marker of early renal disease represents an independent 
predictor of cardiovascular risk in the general population, in addition to hypertensives and 
diabetic patients (112, 113). The European Society of Hypertension concedes the 
importance of Echo measurements, fundoscopy and microalbuminuria in the search for  
EOD occurrence in all hypertensive patients (114). The results of our study provide 
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evidence that the screening for EOD increases the proportion of hypertensive patients who 
should be classified as having a ‘high-risk’ status for cardiovascular mortality and 
morbidity (115).  
 
According to a recent survey, the overall prevalence of chronic kidney disease (CKD) is 
reported to be increasing, and a major proportion of these patients have early CKD in the 
form of microalbuminuria. The prevalence of CKD defined by azotemia was reported to be 
only 0.79% amongst Northern Indians; however, the prevalence of early/sub-clinical CKD 
in the form of microalbuminuria was not considered. Hence, our observations must alert 
physicians to seek evidence for early CKD in hypertension and then initiate 
preventive/treatment strategies. Patients with a high body mass index (BMI), adverse lipid 
profile, risk factors for stroke, and recent vascular insults had a higher incidence for the 
development of microalbuminuria (108, 116-118). However, age and gender was not found 
to play a role in the development of microalbuminuria (23). Significant associations 
between microalbuminuria, retinopathy and LVH have previously been shown in many 
studies (23, 118, 119). Moreover, microalbuminuria was found to be associated with 
coronary artery disease and in the HOPE study, microalbuminuria was selected to be of 
comparable value with respect to the diagnosis of coronary artery disease (119, 120). These 
observations provide much evidence that microalbuminuria serves as a marker of 
generalized endothelial damage, and The European Society of Hypertension in 2007 
justified the assessment of microalbuminuria as a mandatory screening marker for all 
hypertensive patients (121).     
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Patients with one or other components of metabolic syndrome or diabetes often have 
hypertension, which in turn increases the risk of cardiovascular disease and nephropathy 
(122). Hence, it is ideal in clinical practice to perform microalbuminuria in all hypertensive 
patients. Common methods performed to screen for microalbuminuria are (i) albumin to 
creatinine ratio in random urine (ii) 24 hour urine creatinine clearance (iii) a urinary 
dipstick method, and (iv) measurement of albumin excretion rate in timed urine sample. In 
the United States, most physicians prefer a semi-quantitative urinary dipstick approach for 
screening.  
 
The prevalence of LVH in our study of 68% was of a similar value to those reported in 
previous observations (123), and was greater in males, together with those with metabolic 
syndrome (MS) (124). However, another study from Southern  India reported LVH in only 
29% of their hypertensives (23). In this study, associations  between age and LV mass were 
not found, which contrasts with the findings of Shirafkan et. al. (125). There is clearly a 
higher risk for cardiovascular events in hypertensives, coupled with higher risk factors for 
LVH with microalbuminuria. With regard to echocardiographic parameters, hypertensives 
with MS had an increased mean LV mass, wall thickness, left atrial size, longer 
deceleration time and LVH, an observation which concurs with earlier studies (124). 
However, we did not include MS as a component in this study. In MS, the trophic effect of 
insulin on myocardial tissues has been demonstrated in vitro, and this effect could be 
mediated through insulin-like growth factor receptors (126). However, conflicting results 
have been obtained regarding insulin status and LV mass in in vivo studies (126, 127). In 
the primary stages of hypertension, diastolic filling disorder can arise in view of a delayed 
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relaxation of LV, and subsequently, diastolic failure occurs as a consequence of poor LV 
compliance (128). These hypertensive patients with LVH had systolic and/or diastolic 
dysfunction, which concurs with previous observations (109). The pathogenesis of LVH in 
hypertension remains to be fully elucidated; several mechanisms for this process are 
hemodynamic stress, the duration and severity of hypertension (26, 129), and 
neurohumoral factors such as stimulation of the sympathetic nervous system, the renin-
angiotensin-aldosterone system, insulin, and further growth substances which enhance 
myocardial trophic responses (129). Aggressive treatment of LVH is mandatory to prevent 
serious complications arising from it. Table 2.6 provides the differential treatment 














Table 2.6. Treatment considerations for hypertension with end organ damage and  
hypertensive heart disease.  
 
Legend: Table reproduced from Schmieder R. E. (31).       
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Our data suggest that hypertensive retinopathy could be considered as an early ‘marker’ of 
hypertensive EOD (108, 130). Indeed, increased blood pressure may damage the 
microvasculature and induce retinal arteriolar narrowing (131). Furthermore, the 
prevalence of hypertensive retinopathy is higher amongst patients with metabolic 
syndrome (124). It has been shown that there is a strong association between retinopathy 
and LVH (23, 118), whereas Gudmundsdottir et. al. (130) refuted this observation. In this 
study, there was a significant association between increased LV mass and grade II and III 
retinopathy, but not with grade I. It is therefore hypothesised that the duration and severity 
of excessive blood pressure may serve as major contributory factors for both these high 
risk conditions. Numerous previous studies have documented a strong association between 
hypertensive retinopathy and cerebrovascular diseases. Interestingly, the presence of 
hypertensive retinopathy may offer an additional predictive value for clinical stroke risk in 
patients with sub-clinical cerebral disease in imaging studies. In the ARIC study, 
participants with hypertensive retinopathy and with a MRI-defined white matter lesion had 
an 18 times greater risk for the development of clinical stroke than those without either one 
of these factors (132). Additionally, there is a high risk for incident coronary heart disease 
in patients with hypertensive retinopathy (133). Further, hypertensive retinopathy has been 
linked with many other systemic diseases such as heart failure, renal failure, inflammation, 
metabolic syndrome, cognitive impairment and cardiovascular mortality, which were all 
found to be independent of the grades of hypertensive retinopathy (29). Although 
fundoscopy has limitations for the detection of early hypertensive retinopathy (24, 134), it 
does not apply to grades III and IV. Therefore, fundoscopy remains an important tool 
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involved in hypertensive emergencies (24).  Figure 2.2 depicts the evaluation and 
management of hypertensive retinopathy (29).  
 
Figure 2.2. Evaluation and management of patients with hypertensive retinopathy.  
Legend: Figure reproduced from Wong et. al. (29) 
 
Retinal microcirculation provides a tool to assess the systemic microcirculation status. 
Coronary and cerebral microcirculation shares the similar anatomical and physiological 
properties with retinal microcirculation, and hence the pathology elsewhere will be 
reflected in the retinal microcirculation (135). In fact, retinal abnormalities may present in 
the early stage of hypertension which predicts the occurrence of future cardiovascular 
events (136, 137). Cuspidi et. al. observed early retinal changes in 78% in contrast to 22% 
for LVH and 14% for microalbuminuria amongst 800 hypertensive subjects studied (138, 
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139). Fundoscopy is the facile, safe and non-invasive test which provides us with much 
valuable information regarding the retinal vessels, and also aids the diagnosis of 
complications at an early stage (53).  
 
There are some reports which include epistaxis as a form of evidence for EOD in 
hypertensives;  however, this consideration is currently under debate (140). Indeed, the 
potential influence of blood pressure levels on epistaxis requires further investigation. In 
the general population, a blood pressure reduction to values less than 140/90 mmHg is 
recommended, and a target blood pressure of less than 130/80 mmHg is recommended for 
patients with evidence of organ damage or diabetes. The treatment of hypertension is based 
not only on blood pressure, but also on additional factors responsible for the pathogenesis 
of EOD.  
 
2.3.1. Inflammatory and oxidative stress processes in end organ damage 
Inflammatory processes are now being increasingly recognised in the pathogenesis of 
atherosclerosis (141, 142). Inflammation is one of the triggering process in various 
cardiovascular and cerebrovascular events, and thus inflammatory markers may be 
elevated in the hypertensive patients with end organ damage (141, 142). Association 
between C reactive protein (CRP) and future risk for heart attack, peripheral vascular 
disease, stroke and cardiovascular death amongst healthy populations have been published 
extensively (143-145).  
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Heamatocrit has been associated with hypertension and cardiovascular mortality (146). 
Moreover, whole blood viscosity may be implicated in the development of EOD in 
addition to further predictive factors for the development of hypertension as suggested 
above (130, 147). In animal models and hypertensive patients, endothelin receptor blockers 
reduce systemic blood pressure (148). Interestingly, clinical trials aimed at evaluating the 
efficacy of these drugs in the treatment of hypertension, and also in the management of 
EOD in hypertensive patients are underway. Relationships between the incidence of EOD 
and other mediators such as prorenin, renin  and (pro)renin receptors have been previously 
demonstrated (149). Epoxyeicosatrienoic acid (EET) is synthesized from arachidonic acid, 
and exerts beneficial actions towards the cardiovascular system; however, it is converted to 
inactive components by a soluble epoxide hydrolase enzyme (EH). In animal models, 
inhibition of EH has been demonstrated to decrease blood pressure and inflammation, and 
also to protect organs against damage attributable to hypertension (150). Furthermore, an 
EET agonist has shown similar effects in animal model systems. and intriguingly these 
new and novel drugs have reached the point where they are now being evaluated in humans 
(150). It is suggested that ‘oxidative stress’ and inflammation may serve as denominators 
for the induction of end-organ damage in both diabetic and hypertensive populations. In 
addition, a role for α-7 nicotinic acetylcholine receptor (NAR) in inflammation has been 
identified. In hypertensive rats, a deficit in NAR leads to increased blood serum levels of 
pro-inflammatory cytokines (tumor necrosis factor-α, interleukin-1β & 6), which were 
associated with morphological abnormalities in the heart, kidney and aorta (151). 
Treatment of hypertensive rats with an NAR agonist relieved EOD, and diminished the 
levels of pro-inflammatory cytokines. This study concluded that a defect in the cholinergic 
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anti-inflammatory pathway appears to contribute to pathogenesis of EOD, and this may 
provide a new therapeutic avenue for the modern era (151). Figure 2.3 demonstrates the 
schematic presentation of the mechanisms of end organ damage in diabetes and 























Therefore, it is concluded that a very strong relationship exists between hypertension and 
EOD. The evidence for EOD was found to be greater than that expected in newly-
diagnosed hypertensive patients. Hence, a tight control of blood pressure represents the 
first step in the treatment of essential hypertension, which not only retains control of the 
blood pressure, but also serves to prevent or delay the onset/progression of EOD. The 
presence of damage to one or more target organs signifies the requirement for a complete 
evaluation and immediate intensive therapy in the control of blood pressure and the 
treatment of such organ damage, which is likely to reduce the risk of cardiovascular 
mortality. An increased occurrence of EOD in hypertensives observed in this study 
indicates the unawareness amongst the general public, the attitude of physicians, or the 
laxity of the policy utilised for screening techniques. Blood pressure measurements should 
be regularly conducted in clinical practice regardless of the patient’s age, sex and risk 
factors, and the specialty of the practice involved. Consensus guidelines for screening 
measures should be formulated and regularly practiced. Moreover, the physician’s 
awareness of the clinical importance of screening measures in hypertensive patients may be 
strengthened through CME programs, which serve as surrogate markers for the prevention 
and/or treatment of EOD.  
 
In view of covert end-organ damage, viz. microalbuminuria, retinopathy, higher left 
ventricular mass and left ventricular dysfunction observed amongst newly-detected, non-
overweight, non-smoking, non-alcoholic and non-dyslipidemic essential hypertensives in 
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the rural areas in Southern India, there is therefore an urgent requirement to design and 
implement the  “National Hypertension Detection and Control Program” by the Ministry of 
Health and Family Welfare (Government of India), with the help of professional medical 
associations and non-governmental organisations. Indeed, it is time to act (better late than 
never!), in order to prevent or minimise hypertension-induced complications.  
 
2.5. Strengths and Limitations of Study 
Rigid inclusion and exclusion criteria with the regular follow-up of patients served as the 
strengths. The limitations of the study were that it is a report from a single centre, and the 















CHAPTER 3. SEVERE HYPERTENSION IN ELAPID ENVENOMATION 
In this Chapter, three cases of elapid envenomation with severe hypertension requiring 
intravenous anti-hypertensives is presented. Interestingly, snake (krait) bite was unknown 
to all three individuals, but was brought out after an elaborate history and the performance 
of a detailed physical examination. These cases are presented in order to create an 
awareness of such issues amongst those practicing under resource-limited environs wherein 
snake bites are prevalent.  
 
3.1 Case - 1 
A 26-year old male farmer was referred to the emergency room in the early morning from 
peripheral hospital for high blood pressure. He complained of giddiness, abdominal pain 
and vomiting. His past medical or family history was not contributory. He was a non-
smoker, non-alcoholic, and not taking any form of medication. He had never been 
diagnosed to have hypertension, diabetes or kidney diseases, and was neither using 
traditional herbal medication, nor illicit drugs. He also denied febrile episodes, and any 
particular fear, anxiety or emotional distress. On admission, his supine brachial blood 
pressure (BP) was 240/180 mmHg with a strong peripheral pulse, and there was no 
significant difference in measurements between the arms. The physical examination, 
including fundus, revealed no abnormalities. Laboratory tests, including complete blood 
count, serum electrolytes (with an expected low potassium level), hepatic and renal 
function tests, coagulation profile, toxicology screen, urinary catecholamines, and 
renin/aldosterone, were unremarkable. An electrocardiogram showed normal sinus rhythm 
without any evidence of left ventricular hypertrophy. The urinalysis showed no proteinuria. 
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Chest radiograph, ultrasound of the abdomen, and a head-computed tomography scan were 
found to be non-contributory towards hypertension. Meanwhile, 90 min. after admission, 
he developed ptosis and external ophthalmoplegia, and complained of difficulty in 
breathing, swallowing and speaking. He became cyanotic and his level of sensorium started 
declining. He was electively intubated and mechanically-ventilated. Even with adequate 
sedation, there was a fluctuation in heart rate and the BP remained persistently high (range, 
220–240 mm Hg systolic and 160–180 mm Hg diastolic). Though intravenous 
nitroglycerin (NTG) infusion was commenced in order to control hypertension, BP levels 
remained the same as those measured pre-infusion. The rapidly progressive ptosis, 
diplopia, dysphasia, dysarthria, dyspnoea and weakness raised a suspicion of 
neuroparalytic symptoms observable following snake-bite, which is common in rural 
Indian populations. Further careful examination of the patient’s skin revealed a fang mark 
of snake-bite in the lateral aspect of the left leg with evidence of regional lymphadenopathy 
(he did not give a history of any possible snake-bite). On benefit of doubt, the injection of 
polyvalent anti-snake venom (ASV, 10 vials) was instigated. Throughout the next 6 hours, 
his neurological status and hypertension gradually improved, and then nitroglycerin 
infusion was tapered and terminated. He was extubated after 36 hr. of mechanical 
ventilation, and then discharged after 5 days of hospital stay (his BP during the hospital 
stay period was within normal limits). During the follow-up, he was found to be perfectly 
healthy with normal BP values. 
3.2. Case - 2 
A 24-year-old married woman was admitted to the Emergency Department (ED) of our 
hospital with a sudden episode of nausea, vomiting and abdominal pain, and became 
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acutely unwell whilst at work early in the morning. Her periods were normal and 
pregnancy test was negative. There was no past medical history, and she was not receiving 
any regular medications. On examination, she was of normal body weight, and afebrile 
with stable vitals. Her BP was 210/150 mmHg with no postural changes and without 
significant differences in these values between the arms. The physical examination and 
investigations (as outlined in case 1) were within normal limits. One hour after admission, 
the patient developed dysphagia and difficulty in breathing, following which she became 
delirious and experienced apnea. She was immediately put on ventilatory support. She had 
bilateral ptosis with reactive pupils. A thorough history of her family’s dwellings and 
sleeping habits revealed the crucial evidence. Being farmers, they resided close to the 
fields and had frequently slept on the floor. Further careful examination of the patient’s 
skin revealed a fang mark characteristic of snake-bite in the dorsum of her right foot, with 
evidence of regional lymphadenopathy.   Based on clinical findings and corroborative 
evidences, 10 vials of polyvalent ASV in 100 ml of 0.9% saline was administered to her. 
During the following 6 hr., she displayed marked neurological improvement and her BP 
values diminished. She was weaned off the ventilator 36 hr. later and was discharged from 
the hospital on day 4. During the follow-up, she was perfectly healthy with normal BP 
levels.  
3.3 Case - 3 
A 35-year old male presented to the ED with abnormal sensations all over his body when 
he got up from sleep early in the morning. He also had nausea, abdominal pain and 
giddiness; he had no other significant past medical history. On examination, his BP was 
200/140 mmHg with a normal general and systemic examination. The pertinent laboratory 
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parameters and imaging tests (detailed in case 1) revealed no abnormalities. He was kept 
under observation for further evaluation and NTG infusion was commenced. He 
subsequently developed acute paralysis with respiratory failure 2 hr. later on arrival at the 
hospital. He was intubated and then put on continuous mechanical ventilation. At this 
point, he had partial ptosis, dilated pupils, complete external ophthalmoplegia, and flaccid 
quadriparesis, with a flexor plantar response. A fang mark characteristic of snake-bite was 
seen in the lateral aspect of the right leg and he was started on a standard dose of inj. ASV. 
After 2 hr. of ASV infusion, he began to show spontaneous respiratory effort and required 
mechanical ventilation for a further 12 hr., although his BP became normal within 3 hr. of 
commencement of ASV. His neurological manifestations resolved over the next two days, 




In all 3 cases, the snake was identified as a krait based on the classical history, clinical 
picture and increased incidences of krait bite in the local area. It is well known that kraits 
are active and agile at night, and during the rainy season they frequently seek refuge in dry 
places, such as those inside a house or dwelling place. Additionally, if humans are bitten by 
this snake during their sleep, they are seldom aware of it, since their experience of the bite 
generally resembles that from an ant or a mosquito, a phenomenon giving rise to a false 





Elapid envenomation predominantly gives rise to neurotoxicity, a  consequence of 
neuromuscular blockade, which manifests as paralysis of the bulbar, ocular, limb and 
respiratory muscles, leading to respiratory failure (153). The elapid venom contains both 
pre-synaptic and post-synaptic neurotoxins; however,  krait venom exerts a predominant 
action in pre-synaptic neurons (153). Predominantly, pre-synaptic neurotoxins present in 
the venom of Bungarus species are highly potent and suppress the capacity of neuron 
endings to release biochemical transmitters. Transmitter release is primarily blocked 
subsequent to envenomation with such bangarotoxins (giving rise to a brief paralysis), a 
process followed by a period of substantial over-excitation (including cramps, spasms and 
tremors), which, in turn, leads to further paralysis. 
 
Hypertension in our cases is probably ascribable to snake venom, since the secondary 
causes of hypertension were ruled out. Moreover, blood pressure levels  normalised 
following ASV therapy, and the recoveries from neuromuscular paralysis observed indicate 
that krait venom might have contributed towards hypertensive episodes in such cases. 
Autonomic dysfunction following snake-bite may induce various symptoms such as 
abdominal pain, vomiting, sweating, and mild to moderate hypertension or hypotension, 
and cardiac arrhythmia. In a previous study, it was observed that more than 50% of the 
patients with krait bite had elevated blood pressure (154). However, severe hypertension 
subsequent to snake envenomation and requiring intravenous NTG is under-reported (155). 
The pathogenesis for autonomic dysfunction in snake bite is unclear. However, it may be 
attributable to the pre-synaptic alpha-2 adreno-receptor inhibition by elapid neurotoxin, 
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thereby blocking inhibition of the neutrally-mediated release of nor-epinephrine. Hence, 
this process gives rise to sympathetic over-activity and decreased parasympathetic 
stimulation (154, 156). A patient who was bitten by a Malayan krait experienced sweating, 
tachycardia, dilated pupil and hypertension arising from parasympathetic abnormalities 
(157).  
 
In a case of a vipera berus bosniensis bite in Hungary, a high BP of 200/120 mmHg was 
recorded, with the victim responding promptly to the administration of an angiotensin-
converting enzyme (ACE) inhibitor. Hence, the authors of this particular case report 
suggested that the venom of certain of the vipera population may contain cardiotoxin, 
which has potential to act at or via autonomic synapses (158); moreover, snake venom 
releases catecholamines which influence BP (159). Hypertension without neurotoxic 
symptoms was observed in patients with Western Russell’s viper envenomation (160), and 
neurotoxic signs without hypertension was observed in an episode of the Eastern Russell’s 
viper envenomation. It therefore appears that different toxins are responsible for 
cardiovascular and neurological symptoms (159). Further attributable causes for 
hypertension are pain, distress or hypoxia. However, severe hypertension in such cases is 
extremely rare. Additionally, the normalisation of blood pressure with improvements in  
   
3.6. Conclusion 
In conclusion, physicians should consider the possibility of severe hypertension in 
neurotoxic snake envenomation which may be ascribable to autonomic storm. Such 
patients may require intravenous NTG for the control of hypertension, together with other 
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conventional management protocols for snake bite. The drug of choice for the management 
of severe hypertension in such cases is NTG. Preferably, beta-blockers should be avoided 
in such situations where there is an excess of catecholamines, since these agents can 
precipitate severe alpha-agonist effects via the blockage of beta-receptor effects.  
 
3.7. Strengths and limitations of the study 
The fatal complication of snake envenomation, i.e. hypertension, is highlighted, as is the 
role of anti-hypertensive drugs to manage it. Limitations are the small number of subjects 
(patients) involved and non-confirmation of snake bite by immunoassay methods in view 
of technical limitations and the unavailability of facilities to perform such tests. Hence, 
more studies are warranted to establish the relationship between severe hypertension and 

















CHAPTER 4. BLOOD PRESSURE COMPONENTS IN THYROID DISORDERS 
4.1.Methodology 
This study was performed at a tertiary care center in Southern India after the acquisition of 
approval from the Institutional research Ethics Committee, and also on receipt of informed 
consent from each participant recruited to the investigation. The ethical clearance approval 
was obtained from Ethical committee, Chennai Medical College Hospital & Research 
Centre,  Trichy, India.  
 
Subject criteria 
Rigid inclusion and exclusion criteria were applied to recruit adult participants with thyroid 
dysfunctional status (established hypothyroid and hyperthyroid cases) and healthy control 
(euthyroid) subjects. Subjects with co-existing morbidities such as diabetes, post-
thyroidectomy status, cardiovascular diseases, renal dysfunction and other illnesses were 
excluded from the study. Also, all the subjects recruited to this study were non-smokers 
(never smoked) and non-alcoholic, and all of them consumed normal salt intake. There 
were 71 hyperthyroid and 300 hypothyroid cases, and 300 control subjects.  
 
Anthropometric (height and weight) and BP components were determined for all these 
participants. For the purpose of this study, the BP components considered are systolic BP 
(SBP), diastolic BP (DBP), mean arterial pressure (MAP), and SBP:DBP ratio. MAP 
values were computed using the [DBP + 1/3(pulse pressure)] formula, where pulse 
pressure represents the difference between the SBP and DBP values. Body mass index 
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(BMI) was calculated using the formula weight in kg/(height in meters)
2
. A BMI value 
23.0 and above was considered as overweight according to the WHO for Indians (161). 
 
Thyroid function evaluation 
Thyroid-stimulating hormone (TSH) and free thyroxine (T4) were estimated in all subjects 
by immunoradiometric assay (IRMA) using kits procured from Board of Radiation and 
Isotope Technology (BRIT), Mumbai, India. Normal reference population values of TSH 
and T4 are 0.17 - 4.05 IU/ml and 55 - 135 ng/ml respectively.  
 
Statistical Analysis of Experimental Data Acquired 
Univariate data analysis of SBP, DBP, SBP:DBP ratio, MAP, BMI, age, and blood serum 
TSH and T4 level indices [analysis of variance (ANOVA), analysis of covariance 
(ANCOVA) and χ
2
 contingency table analysis] was performed using XLSTAT software. 
ANOVA and ANCOVA were conducted both with and without the inclusion of first-order 
interaction variance components, and also with a tolerance of 0.0001 and the computation 
of 95% confidence intervals (CIs) for the least squares means determined. In cases where 
there were heterogeneous intra-sample variances, comparisons of mean thyroid status 
values were performed using the Welch ANOVA method. Post-hoc analysis of the 
differences between the mean values of all group classifications was performed by Tukey’s 
honestly significantly difference (HSD), Fisher’s least significant difference (LSD), and the 
Bonferroni and Dunn-Sidak tests. Partial correlation coefficients [and their corresponding 
two-tailed significance (p) values] were computed between a MV dataset containing the 
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serum T4 and TSH biomarker concentrations (together with age and BMI values) and each 
of the BP components individually.   
 
Multivariate Redundancy Analysis (RDA) was also performed with XLSTAT software, the 
model involving a minimum filter factor of 80%; permutations were performed 500, 1,000 
or 2,000 times, and both response (BP) and explanatory (thyroid disease) variables were 
centered and reduced prior to analysis (a 1% significance level was employed), and 
weighted average (WA) scores were employed for the response variables. For partial RDA, 
a preliminary stage was performed in which the explanatory variables (thyroid status, both 
with and without serum T4 and TSH biomarker concentrations and/or BMI, age and 
gender) table was sub-divided into two groups, the first of which [X(1)] contained 
conditioning variables (BMI, age and gender), the effect of which was removed, since their 
effects on BP components are already known). Regressions were then performed on the Y 
(blood pressure) and X(2) (thyroid status, both with and without serum TSH and T4 levels) 
tables, and the residuals of the regressions arising were then employed for the RDA step. In 
this manner, we analysed the effects of the second [X(2)] group of variables, i.e. that 
remaining after the effect of the first [X(1)] group of conditioning variables had been  
removed. 
 
Canonical correlation analysis (CCA) was also performed using XLSTAT software and a 
minimum filter factor of 80%, as was principal component analysis (PCA). PCA was 
conducted both with and without a subsequent Varimax rotation (the latter with Kaiser 
normalisation and a maximum of 4 components), and the application of Bartlett’s 
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4.2.1. Descriptive statistics 
The overall mean age for hyperthyroid, hypothyroid and euthyroid control patients were 
35.59 yr.; 34.15 yr.; and 38.40 yr.; respectively. The range and mean values of BP 
components for hyperthyroid, hypothyroid and euthyroid control patients were SBP: 108 to 
150, and 127.04 mmHg; 80 to 200, and 120.31 mmHg; 90 to 160, and 115.04 mmHg; 
respectively. DBP: 48 to 92, and 77.80 mmHg; 60 to 140, and 80.59 mmHg; 70 to 100, and 
77.28 mmHg respectively; MAP: 68.67 to 110.00, and 94.04 mmHg; 73.33 to 160.00, and 
93.83 mmHg; 76.67 to 120, and 89.87 mmHg respectively. SBP:DBP ratio: 1.3750 to 
2.2917, and 1.637; 1.1429 to 1.8333, and 1.495; 1.1250 to 1.8286, and 1.492 respectively. 
 
Similarly, the range and mean BMI values for hyperthyroid, hypothyroid and euthyroid 
control patients were 14 to 21, and 17.71 kg.m
-2
; 13 to 33, and 22.39 kg.m
-2
; 16 to 24, and 
21.38 kg.m
-2
 respectively. The range and mean values of serum thyroid disease biomarkers 
for hyperthyroid, hypothyroid and control euthyroid patients were TSH: 0 to 0.13, and 
0.085 IU/ml; 26.00 to 100.00, and 75.00 IU/ml; 0.10 to 5.10, and 2.07 IU/ml respectively. 
T4: 160.00 to 240.00, and 198.52 ng/ml; 50.00 to 113.00, and 65.53 ng/ml; 55.00 to 




4.2.2. Univariate Statistical Analysis 
ANOVA of the dataset revealed very highly significant differences between the  disease 
classifications for (1) SBP, the mean values [Figure 4.1(a)] being in the order Hyperthyroid 
>> Hypothyroid > Euthyroid (p < 0.0001); (2) DBP, the mean value [Figure 4.1(b)] order 
being Hypothyroid > Hyperthyroid ≅ Euthyroid (p < 0.0001); (3) SBP:DBP ratio, the mean 
value [Figure 4.1(c)] order being Hyperthyroid >> Hypothyroid ≅ Euthyroid (p < 0.0001); 
(4) MAP, the mean value [Figure 4.1(d)] order being Hyperthyroid ≅ Hypothyroid >> 
Euthyroid (p < 0.0001); and finally (5) BMI, the mean value [Figure 4.1(e)] order being 
Hypothyroid > Euthyroid >> Hyperthyroid (p <0.0001). The mean serum TSH [Figure 
4.1(f)] and T4 [Figure 4.1(g)] levels were in the order hypothyroid >> euthyroid >> 
hyperthyroid (p < 0.0001), and hyperthyroid >> euthyroid >> hypothyroid (p < 0.0001) 





































Figure 4.1 (c ) Univariate statistical analysis – SBP/DBP (systolic blood pressure: diastolic 






















































Table 4.1. Mean ± 95% confidence intervals (CIs) for SBP, DBP, SBP:DBP ratio, MAP, 
BMI, T4 and TSH level, and Age parameters determined for Hypothyroid (n = 300), 
Hyperthyroid (n = 71) and Euthyroid (n = 300) patients. The significance of differences 
between the mean values of the three thyroid status classifications were determined by 
ANOVA (Section 2).  




















0.00016 Hyperthyroid  127.04 ± 3.30 









0.002 Hyperthyroid  77.80 ± 1.46 









< 0.0001 Hyperthyroid  1.637 ± 0.040 









Ns Hyperthyroid  94.04 ± 1.77 









< 0.0001 Hyperthyroid  17.71 ± 0.32 
Euthyroid  21.38 ± 0.16 
 
 
Serum T4 level 
(ng/ml) 





< 0.0001 Hyperthyroid  198.52 ± 4.04 










< 0.0001 Hyperthyroid  0.085 ± 0.008 









Ns Hyperthyroid  35.59 ± 2.75 
Euthyroid  38.36 ± 1.54 
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Abbreviations: ns, not significant. BMI – body mass index, MAP – mean arterial pressure, 
SBP – systolic blood pressure, DBP – diastolic blood pressure, T4 and TSH – thyroid 
hormones 
 
As expected, analysis of the untransformed datasets revealed that there were also highly 
significant differences between the variances (‘scatter’) of these BP components between 
thyroid status groups, for example Hypothyroid ≅ Hyperthyroid >> Euthyroid for SBP (p < 
0.0001); Hypothyroid >> Hyperthyroid > Euthyroid for DBP (p < 0.0001); Hyperthyroid 
>> Hypothyroid ≅ Euthyroid for SBP:DBP ratios (p = 0.005); and Hypothyroid >> 
Hyperthyroid > Euthyroid for MAP (p < 0.0001). Interestingly, the variance of the BMI 
values of the hypothyroid patient group was found to be much greater than those of both 
the euthyroid and hyperthyroid patient groups (p < 0.0001). 
 
Focusing on the SBP:DBP ratio in view of the clear, highly significant differences in this 
parameter between the disease classification groups, further univariate analysis was 
performed. An ANCOVA model without allowing for any interaction effects demonstrated 
that there were extremely highly significant differences between Disease Classifications (p 
< 0.0024), again predominantly ascribable to the much higher SBP:DBP ratio of 
hyperthyroid patients than those of hypothyroid and euthyroid status, and also that serum 
T4 and TSH concentrations exerted highly significant effects as covariates (p < 0.0001 and 
0.00572 respectively) on this BP component; all further (explanatory) covariates, i.e. BMI 
values, age and gender, were found to not exert a significant influence on this (dependent) 
SBP:DBP ratio variable. Standardised regression coefficients (and the sign of these 
contributions) for each of the significant covariates in this model were in the order 
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hyperthyroid status (+) > euthyroid status (-) > hypothyroid status (-) > serum TSH level (-
) > serum T4 level (+), i.e. there were positive and negative contributions of serum T4 and 
TSH concentrations towards the SBP:DBP ratio dependent variable, as expected.   
ANCOVA performed with allowance for all possible first-order interaction effects 
demonstrated that the serum TSH level-thyroid status interaction component of variance 
was extremely significant (p < 0.0001), with also a significant effect for the serum T4-TSH 
concentrations interaction effect (p = 0.01024).  
 
Figure 2 exhibits plots of BMI versus age, and SBP:DBP ratio, MAP, and serum TSH and 
T4 levels versus BMI. Also shown are plots of SBP:DBP ratio versus BMI, serum T4 and 
serum TSH concentrations. The plot of BMI versus age revealed at least some distinction 
between the euthyroid and hyperthyroid groups [Figure 4.2(a)], as did that of MAP versus 
BMI [Figure 4.2(b)]. However, the plot of serum TSH level versus BMI [Figure 4.2(c)] 
shows a high level of discrimination between all three thyroid status classifications, 
whereas there was also a very clear separation visible between the hyperthyroid and both 
the euthyroid and hypothyroid groups (with also at least some distinction between these 
latter two groups) in the plot of serum T4 level versus BMI [Figure 4.2(d)]. Plots of 
SBP:DBP ratio versus BMI [Figure 4.2(e)] clearly showed that hyperthyroid patients had a 
very significantly higher SBP:DBP ratio and lower mean BMI values than those of both 
healthy control and hypothyroid patients. Moreover, particularly notable was the 
observation that plots of SBP:DBP ratio versus serum T4 and TSH concentrations [Figures 
4.2(f) and 4.2(g) respectively] exhibited high levels of distinction between the three thyroid 
disease status classifications.  
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Figure 4.2 (e) ANCOVA – SBP/DBP (systolic blood pressure: diastolic blood pressure 









Figure 4.2 (f) ANCOVA - SBP/DBP (systolic blood pressure: diastolic blood pressure 









Figure 4.2 (g) ANCOVA - SBP/DBP (systolic blood pressure: diastolic blood pressure 









Based on a BMI threshold cut-off of 23.0, we examined the frequencies of euthyroid and 
hypothyroid patients within each of the thyroid disease classification groups (< 23 and 
those with values ≥ 23) via a χ
2 
contingency table analysis, and found that there was a very 
strong association between these two classification criteria [(p < 0.0001, Monte-Carlo 
simulation, Figure 4.3(a)], with a much higher proportion of hypothyroid patients in the 
elevated BMI group [odds ratio of 15.12 (95% CI 9.33-24.50) and a likelihood ratio of 
7.26]. Similarly, we also explored the association between this BMI classification and 
euthyroid vs. hyperthyroid status [Figure 4.3(b)], and also found a significant association 
between these two criteria (p = 0.018), with a PETO odds ratio of 3.72 (95% CIs 1.28-















Figure 4.3 (a) χ
2 
contingency table analysis – body mass index and thyroid status 









Figure 4.3 (b) χ
2 
contingency table analysis – body mass index and thyroid status 










4.2.3 Multivariate Statistical Analysis 
Partial Correlation Analysis 
We employed partial correlation analysis in order to explore similarities/dissimilarities 
between a MV dataset (consisting of patient serum T4 and TSH biomarker levels, BMI and 
age), and each of the four BP components (SBP, DBP, MAP and SBP:DBP ratio), the latter 
on an individual basis in view of interfering multicollinearity problems arising from the 
relatively high positive correlations existing between each of these BP parameters (either 
previously established or, for the SBP:DBP ratio index, discovered here). Partial 
correlation was chosen as an optimal method for the investigation of these relationships 
since it serves to provide realistic representations of relationships between the thyroid 
status and BP parameters in view of their independence of the influence of (i.e. co-
correlations with) further, potentially interfering variables (unlike simple Pearson 
correlation coefficients). On consideration of the clear ‘between-thyroid status’ differences 
in such relationships, we computed partial correlation coefficients [rbp(n).th(1-4)] for each 










Table 4.2. Partial correlation coefficient (rbp(n).th(1-4)) values between individual BP 
components and blood serum TSH and T4 biomarker levels (IU/ml and ng/ml 
respectively), age (yr.) and BMI (kg.m
-2
) parameters. The corresponding two-tailed 




Parameter SBP DBP MAP SBP:DBP 
Hypothyroid TSH level 0.1359 (0.0191) 0.1864 (0.00125) 0.1745 
(0.00255) 
Ns 
T4 level Ns ns Ns Ns 
Age 0.1939 (0.00078) 0.2144 (0.00020) 0.2194 
(0.00014) 
 
BMI 0.2589 (< 
0.00001) 




Hyperthyroid TSH level Ns ns Ns Ns 
T4 level Ns 0.3498 (0.0035) 0.29064 ( 
0.0162) 
Ns 
Age 0.3382 (0.0048) 0.3931 (0.00091) 0.40781 
(0.00056) 
Ns 
BMI Ns ns Ns Ns 
Euthyroid TSH level Ns ns Ns -0.1192 
(0.0401) 
T4 level 0.1432 (0.0135) ns 0.1423 
(0.0140) 
Ns 
Age Ns ns Ns Ns 
BMI Ns ns Ns Ns 
Abbreviations: ns, not significant. BMI – body mass index, SBP – systolic blood pressure, 




Although all the rbp(n).th(1-4) values computed are relatively small, approximately one-
third of them were statistically significant in view of the very large sample sizes employed 
in this investigation. Firstly, for the hypothyroid status group of patients, individual SBP, 
DBP and MAP values all significantly positively correlated with serum TSH concentration, 
BMI and age, whereas the SBP:DBP ratio index only correlated significantly and 
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positively with BMI. Secondly, and in contrast, the hyperthyroid status classification 
exhibited strong positive correlations of the individual DBP and MAP BP components with 
both the serum T4 level (p = 0.0035 and 0.0162 respectively) and age (p = 0.00091 and 
0.00056 respectively) explanatory variables; the SBP component was only significantly 
positively correlated with age, and no significant correlations of the SBP:DBP index to any 
of the explanatory variables were found. Thirdly, for the euthyroid (healthy control) group, 
significant positive correlations were found between the SBP, DBP and MAP components 
and serum T4 concentration, whereas, interestingly, a significant negative one was found 
between the SBP:DBP ratio parameter and serum TSH concentration. These results 
acquired are at least partially consistent with those acquired from the further MV analysis 
performed.    
          
Permutation tests via Redundancy Analysis (RDA) 
Primarily, we performed a series of permutation tests via RDA in order to explore 
relationships between BP components and thyroid disease status with its associated serum 
T4 and TSH biomarker level datasets. This test served to determine whether or not the 
thyroid status  classifications of the study participants is significantly improved over that 
arising from any other random classification of these groups; the class labels of the 
euthyroid, hypothyroid and hyperthyroid patients were permuted, and then randomly 
assigned to different patients. With these ‘incorrect’ disease class labels, a classification 
model was again computed; hence, the rationale was that with these ‘incorrect’ class labels, 
the computed model for classification purposes should be ineffective at class prediction 
(since the groups are generated randomly, the null hypothesis is that there are no 
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differences between them). With repetition of this permutation test many times (500, 1,000 
or 2,000 times in this investigation), a null distribution of classifications which are 
expected to be insignificant were formed, and if the computed statistic (pseudo-F) lies 
outside at least the 95% or 99% confidence bounds of this distribution, then it could be 
concluded that there is a significant (linear) relationship between the two sets of 
parameters.  
 
In this manner we utilised four experimental models: (1) a full RDA in which relationships 
between all BP components (SBP, DBP, SBP:DBP ratio and MAP values as response 
variables) to all thyroid status classifications (hyper and hypothyroid, and euthyroid) and 
biomarkers (serum T4 and TSH levels), together with BMI, age and gender as explanatory 
variables; (2) a partial RDA in which the conditioning effects of the BMI, age and gender 
variables were removed from model (1); (3) a somewhat simpler full RDA model in which 
all of the above BP components served as response variables, and only the thyroid status 
classification was employed as the explanatory variable; and (4), as (3), but a partial RDA 
in which the conditioning effects of the BMI, age and gender variables were again 
removed. 
 
Extremely highly significant relationships were found for all of the above four 
experimental models (p < 0.0001), results which clearly demonstrated powerful 
associations between thyroid disease status and each of the four BP components examined 
(Figure 4.4). Indeed, for model (1), only the first and second factors significantly 
contributed to the total variance (80 and 20%, respectively), and the order of each factorial 
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contribution for the explanatory variables was euthyroid disease status > BMI > age > 
serum TSH level > hypothyroid disease status > gender for factor 1, and hyperthyroid 
disease status and serum T4 level for factor 2, i.e. the second component was ascribable to 
the hyperthyroid condition [these two factors represent linear combinations of (correlated) 
quantitative explanatory variables and are orthogonal (uncorrelated) to each other]. For the 
BP component (response) variables, however, contributions to factor 1 were MAP > SBP > 
DBP values, whereas, as expected, only the SBP:DBP ratio (highly significantly elevated 
in hyperthyroid patients over those in the hypothyroid and euthyroid classifications) 


























Canonical Correlation Analysis (CCA) 
CCA analysis performed on the complete centered/reduced datasets revealed that there was 
an extremely strong relationship between the quantitative thyroid disease classification 
variables (blood plasma T4 and TSH levels, together with age and BMI values) and the BP 
component dataset (SBP, DBP, SBP:DBP ratio and MAP values p < 0.0001), which 
featured two significant factors (Wilks’-Lambda test), and hence there were two highly 
statistically significant dimensions between these two sets of variables (Figure 4.5). As 
noted above for the RDA conducted, BP variables contributing to factor 1 were MAP 
(correlation -0.990) > SBP (-0.948) > DBP (-0.855) values, whereas only the SBP:DBP 
ratio contributed significantly to factor 2 (correlation 0.922). There was also a notable 
canonical correlation between the SBP:DBP ratio parameter and serum T4 concentration, 
the latter also exhibiting a very strong positive correlation to factor 2 (0.980). Age was 
strongly negatively and positively correlated to factor 1 and MAP values respectively, and 
there was a moderate positive correlation between this variable and BMI values. However, 
BMI was negatively correlated to both factors 1 and 2, and there was also a strong positive 
correlation between this variable and serum TSH concentrations, which presumably arises 

















Overall, the correlations between the explanatory variables significantly contributing to 
factor 1 were in the order BMI > age ≅ serum TSH level, and that exerting an influence, 
albeit a substantial one, on factor 2 was only serum T4 concentration (the correlation of 
this variable  with the second canonical dimension was 0.98). These results demonstrate 
that the second canonical dimension is ascribable to the hyperthyroid status classification, 
results which are entirely consistent with those acquired by RDA.    
 
CCA was also performed on the individual thyroid status patient groups; as expected, 
relationships between the above quantitative thyroid disease classification variables and the 
BP component dataset were found to be significant for only the hypo and hyperthyroid 
status classifications, and each of these analyses exhibited only one significant dimension 
(p < 0.0001 for both the hypo and hyperthyroid classifications, Wilks’-Lambda test). For 
the hypothyroid status group, the BP component dataset was found to be most strongly 
influenced by the BMI > age > serum TSH level variables (all negatively correlated to the 
only significant canonical dimension), whereas for the hyperthyroid one, the dominating 
thyroid status variables were in the order age > serum TSH level > BMI (also all negatively 
contributing to the significant dimension). These results also at least partially reflect the 
significantly elevated mean BMI value of the hypothyroid status group over that of the 





Principal Component Analysis (PCA) 
PCA analysis of a (simplified) dataset, which included only the BP components as 
predictor variables, and only thyroid status as a (qualitative) supplementary one, revealed 
at least some ‘clusterings’ of the these thyroid status classifications, the differences 
observed between the hyperthyroid and euthyroid groups being especially notable (Figure 
4.6 shows a plot of principal component 2 (PC2) versus principal component 1 (PC1) for 
the varimax-rotated dataset). As noted for the RDA and CCA performed above, for this 
form of MV analysis, SBP, DBP and MAP values were significant contributors to PC1, 
whereas only the SBP:DBP ratio significantly contributed to PC2. PC1 and PC2 accounted 



























Univariate statistical analyses revealed extremely highly significant 'between-thyroid 
status' differences (p < 0.0001) for the SBP, DBP, MAP, and uniquely the SBP:DBP ratio 
parameters. Moreover, BMI was significantly elevated in hypothyroid status patients over 
those of the healthy control and hyperthyroid status groups (p < 0.0001), and healthy 
controls had a significantly greater mean BMI value than that of hyperthyroid patients (p < 
0.0001). χ
2
 contingency table analysis revealed very strong associations between 
overweight status (BMI < or ≥ a threshold value of 23) and (1) euthyroid and hypothyroid 
disease status classifications (p < 0.0001) and (2) euthyroid and hyperthyroid 
classifications (p < 0.018). Partial correlation analysis demonstrated significant or highly 
significant correlations of (1) SBP, DBP and MAP BP components with blood serum TSH 
level for the hypothyroid group (all positive); DBP and MAP values with serum T4 
concentration for the hyperthyroid group (also both positive); and intriguingly, SBP, DBP 
and MAP indices with serum T4 level (all positive), plus a negative one between SBP:DBP 
ratio and serum TSH concentrations for the euthyroid group. These results clearly indicate 
the importance and significance of systolic and/or diastolic hypertension in hypo and 
hyperthyroidism.    
   
MV permutation tests performed via RDA demonstrated powerful associations between 
thyroid disease status and each of the BP components. Moreover, CCA of the complete 
(i.e. the combined hyperthyroid, hypothyroid and euthyroid status groups) revealed two 
highly significant dimensions between the BP component dataset and that comprising both 
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serum thyroid status biomarkers, age and BMI values, the first containing marked 
influences from SBP, DBP, MAP (response variables) and serum TSH concentration, BMI 
and age (explanatory variables), whereas the second contained highly significant 
contributions from SBP:DBP ratio (response variable) and serum T4 level (explanatory 
variable), i.e. the second dimension was ascribable to the hyperthyroid status classification, 
results consistent with those acquired from the above RDA conducted. PCA scores plots 
revealed at least some clustering of the three thyroid status classifications, and, as observed 
with CCA performed, the SBP, DBP and MAP values were found to be significant 
contributors to the first principal component, whereas only the SBP:DBP ratio significantly 
contributed to the second. 
 
Although essential hypertension is more common, secondary hypertension is increasing 
and is now prevalent in view of associated disorders, which are more common in females 
(162). Furthermore, thyroid disorder is the most common endocrinological disorder, and 
hypertension is more often observed in thyroid diseases. However, to date there are only 
limited studies confirming  this association (80). Isolated systolic hypertension is common 
in hyperthyroidism, and systo-diastolic hypertension (with an associated elevated DBP 
rather than SBP values) is prevalent amongst hypothyroid patients (80, 81). Hence, the 
SBP and SBP/DBP ratio components are expected to be greater in hyperthyroid subjects. 
Although both SBP and DBP values are elevated in hypothyroidism, the SBP/DBP ratio 
will be expected to be lower in patients with this condition, as observed here. Moreover, 
since the thyroid status-mediated increase in DBP is greater than that of SBP in 
hypothyroidism, MAP values are also expected to be higher in this class of patients. 
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4.3.1 Mechanisms of hypertension in hyperthyroidism 
In hyperthyroidism, serum T3 and T4 levels are elevated, and its TSH concentration is 
diminished. T3, the active form of the thyroid hormone system, reduces systemic vascular 
resistance through dilatation of the arteriole and relaxation of vascular smooth muscle. 
Hyperthyroidism increases heart rate (HR), cardiac contractility and blood volume, and HR 
is a strong predictor of CO since it affects both systolic and diastolic function (60). In 
hyperthyroidism, HR may be elevated up to 40% of its basal value, and CO increases up to 
300% when compared with that of hypothyroid patients (163). SVR largely regulates 
afterload which, in turn, depends on the arterial compliance and aortic impedance. 
Moreover, an increased capillary density and expression of vascular endothelial growth 
factors have been reported in thyroid diseases (164, 165).  
 
Thyroid hormone-induced vascular muscle relaxation through an increased level of nitric 
oxide (NO) production from endothelial cells has been demonstrated in experimental 
models (165). T3 increases the synthesis of cardiac proteins associated with cardiac 
hypertrophy through the activation of myocyte-specific genes (9). Furthermore, the non-
genomic effect of T3 includes its effect on membrane ion channels for sodium, potassium, 
and calcium, actin polymerisation, mitochondrial proteins and further intracellular cardiac 
signaling pathways (164). The above cardiogenic mechanisms explain the pathogenesis of 
hypertension in hyperthyroidism. However, anti-hypertensive treatment with ACE 
inhibitors in experimental models reduces BP, but not CO and HR (165, 166), suggesting 
the possibility that some other non-cardiogenic mechanisms contribute to hypertension in 
! 120!
thyroid disorders. Even in a hypertensive euthyroid  population, thyroid hormones may be 
associated with left ventricular (LV) remodelling and mass, independent of LV and renal 
dysfunctions (167).  
 
The juxtaglomerular apparatus of the kidney is sensitive to volume and BP. Since T3 
decreases SVR and afterload, there will be a decrease in mean BP, which, in turn, activates 
the RAAS cascade and promotes an elevation in renin synthesis, blood volume and preload 
that contributes to CO value, which is raised in hyperthyroidism (168). An increased 
number of β-adrenergic receptors are found in the renal cortex of experimental models 
with hyperthyroidism, and β-adrenergic stimulation enhances renin secretion (166). 
Additionally, thyroid hormones influence baroreflex function and the autonomic nervous 
system, which are essential for the maintenance of both HR and BP, and hence both play a 
significant role in the development and progression of hypertension.  
 
In view of the above hemodynamic effects, increases and decreases in the SBP and DBP 
components, respectively, will be expected, and consequently pulse pressure will be 
elevated. Pulse pressure serves as a marker of increased arterial stiffness, and also serves as 
a high index factor for cardiovascular risk, especially in the elderly population (169). In a 
previous study, a reduction in nocturnal BP was identified amongst hyperthyroid subjects 
with hypertension (170). An additional investigation involving a 24-hr. BP monitor 
demonstrated a similar mean value of this parameter in normotensive hyperthyroid patients 
when compared to that of normotensive euthyroid individuals (171). Treatment of 
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hyperthyroidism decreases pulse pressure, HR and CO, and subsequently BP. In a further 
report, hypertension was found to normalise to baseline normal range values following 
thyroidectomy for functional thyroid gland adenocarcinoma (172).  
 
Sub-clinical hyperthyroidism (SHY) is characterised by normal serum T3 and T4 levels 
coupled with diminished TSH ones, and this condition is also common. However, 
predominantly, SHY never produces any clinical signs. Interestingly, Tamer et.al. noted an 
increased left ventricular (LV) mass and cardiac workload in SHY patients (173). 
However, to date there is no evidence available for hypertension in SHY patients, which 
has been confirmed by a community-based study (174).  
 
4.3.2.Mechanisms of hypertension in hypothyroidism  
Hypothyroidism is the second most common cause for secondary hypertension (following 
renal hypertension); however, it is often overlooked. The prevalence of hypertension 
amongst hypothyroid patients varies from 1 to 50% (175). Such a substantial variation in 
prevalence is ascribable to variable criteria in defining hypothyroid disease and 
hypertension, and also to differences in the age of subjects studied (176). As discussed 
above, thyroid hormones play a key role in the modulation of hemodynamic parameters. 
Hypothyroidism increases SVR and arterial stiffness in view of its vasoconstrictor effect 
on vascular smooth muscle (177), sympathetic nervous system stimulation, and decreases 
in β-adrenergic receptors (coupled with a parallel increase in α-adrenergic response) (178). 
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Hypothyroidism causes myxedema of the arterial wall which, in turn, gives rise to 
hypertension (177).  
 
Hypothyroidism reduces renal blood flow and the glomerular filtration rate (GFR), with 
inappropriate ADH secretion (i.e., a mildly increased ADH). Consequently, there is free 
water retention with an associated increase in total body water, a decrease in intravascular 
volume and hyponatremia (179, 180). Sodium transport in vascular smooth muscle and the 




) counter transport mechanism; indeed, 




 counter transport (181). Thyroid 




 transport, which  is more pronounced in hypothyroidism, 
and hence hypothyroidism may cause hypertension in this manner (182). In addition, 
hypothyroidism gives rise to low renin and angiotensin levels, which can cause salt-
sensitive hypertension (183, 184). Hypothyroidism is frequently associated with metabolic 
syndrome and obesity (86, 185), which are also predisposing factors for hypertension. 
Elevated plasma TSH concentrations (probable hypothyroidism) in patients with metabolic 
syndrome independent of serum T3 and T4 biomarker values suggest it to be a component 
of the metabolic syndrome (186). Asvold et. al(82) found a linear increase in both systolic 
and diastolic BP components with increasing serum TSH levels in both men and women 
(i.e. significant positive correlations were observed).In a further study, mean day- and 
night-time DBP values were also found to increase linearly with TSH levels (187). 
Intriguingly, diastolic BP elevated significantly during changes from hyperthyroidism to 
hypothyroidism, and also normalised to normotensive values after the achievement of 
euthyroid status and low plasma renin levels in hypertensive hypothyroidism (188).  
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Sub-clinical hypothyroidism (SHO) is classified as a condition associated with high serum 
TSH, but normal serum T3 and T4 concentrations, with or without clinical symptoms; 
however, this condition has been associated with diastolic hypertension (174). Various 
studies have indicated an association of hypertension with SHO (84, 174, 189), whereas 
Duan et. al. (8) did not find any such association. Notwithstanding, Dagre et. al. (190) 
found a strong relationship between SHO and both systolic and diastolic classes of 
hypertension. Moreover, endothelial dysfunction is more prevalent in hypothyroid patients 
(191), and pregnant women with sub-clinical hypothyroidism have an increased risk for 
severe pre-eclampsia when compared with euthyroid subjects (192). 
 
In one study (44), an elevated serum TSH concentration was noted in families with a high 
prevalence of hypertension, which suggests the possibility of genetic polymorphism of this 
biomarker with type-2 iodothyroninedeiodinase genes which are involved in the 
modulation of BP regulation and serum levels of this biomarker. In hypothyroid patients, 
treatment with T4 reduces arterial stiffness, vascular resistance and BP (190). Hence, early 
diagnosis and management are required in such patients in order to reduce cardiovascular 
risk status.  
 
4.3.3 Treatment of hypertension in thyroid disorders 
In thyroid disorders, hypertension is reversible once thyroid function attains normalisation 
status, although this may not necessarily occur shortly thereafter. However, treatment with 
antihypertensive drugs is mandatory in the case of moderate to severe hypertension. 
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Isolated systolic hypertension represents the strongest risk factor for cardiovascular 
disease, which is common in hyperthyroidism (80). β-adrenergic blockers are preferred in 
such cases, since they not only reduce BP, but also alleviate further symptoms of 
hyperthyroidism such as tremor, tachycardia and anxiety (193). Propranolol inhibits the 
peripheral conversion of T4 to T3, a more active form of these thyroid hormones. 
Individuals with relative contra-indications for β-adrenergic blockers may tolerate β1-
selective drugs more effectively. Calcium channel blockers (CCBs) may be considered if 
patients are unable tolerate β-blockers, and felodipine has been shown to reduce BP and 
SVR in hypertensive hypothyroid patients who did not respond to hormone replacement 
(194). ACE inhibitors offer a potential benefit to hypertensives with thyroid disorders, 
since they reduce intraglomerular pressure (168). In most cases, hypertension associated 
with hypothyroidism is salt-sensitive, although in hyperthyroidism it is salt-resistant. 
Hence, a typical salt-sensitive and low renin form of hypertension is frequent in 
hypothryroidism, and this is more effectively treated with a low sodium diet, CCBs and a 
diuretic. 
 
4.3.4. Effect of treatment of thyroid disorders on blood pressure 
In a study conducted by Dernellis et. al., hypothyroidism was associated with hypertension 
and aortic stiffness. Amongst the patients who received thyroid replacement therapy, 50% 
of them showed reversibility in their hypertension and aortic stiffness was decreased 
among all patients. After the achievement of euthyroid state in hyperthyroid patients who 
received treatment, atrial fibrillation reverted to sinus rhythm in the majority of patients 
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(195).  In a cohort study conducted by Razvi et. al., thyroid replacement therapy is found to 
be beneficial in patients with SHO in the terms of cardiovascular events and mortality 
(196). It is noted that ventricular function improves with thyroid replacement therapy even 
in SHO (196). In the settings of ischemic heart disease, treatment of hypothyroidism 
proven to offer clinical benefits such as reduction of blood pressure, afterload and cardiac 
output and there by decrease the oxygen demand ischemia (176).  
4.3.5. Need for TSH testing 
The International classification of diseases ninth edition (ICD – 9) recommends screening 
TSH testing for the following diagnosis as listed in the table 4.3 (61).  
 





Isolated systolic hypertension and an increased pulse pressure are more common in 
hyperthyroidism, whereas combined systo-diastolic hypertension (in which elevations in 
DBP exceed those in SBP) is more pronounced in hypothyroidism. We have also noted 
significant associations between SBP:DBP ratios, MAP values, and thyroid disease status. 
Indeed, employment of the SBP:DBP ratio may serve as a valuable diagnostic index for 
monitoring the development of hypertension and its response to treatment in hyperthyroid 
patients. Therefore, practitioners may be motivated to record BP in thyroid disorders and 
provide appropriate medications in order to reduce cardiovascular mortality/morbidity 
risks. The use of 24 hr. ambulatory BP measurements will not only facilitate this diagnosis, 
but also provide valuable information regarding load, circadian variation and BP 
variability, which are all considered as important risk factors and surrogate markers for 
cerebro and cardiovascular events.  
 
4.5. Limitations 
The limitations of this investigation are that correlations of the dataset acquired with 
duration of illness were not explored. 24 hr. ABP was not utilised and there was not a 
follow-up of BP in these patients subsequent to the initiation of specific thyroid disease 
treatment(s), and the non-estimation of serum T3 levels (each of these are ascribable to 





CHAPTER 5: KNOWLEDGE, ATTITUDE, BEHAVIOUR AND PRACTICE 
(KABP) OF HYPERTENSION MANAGEMENT AMONG PHYSICIANS 
5.1 Methodology 
A structured questionnaire was distributed amongst the 117 physicians practicing in urban 
parts of India and of these, 104 physicians responded. However, amongst the 104 
questionnaires returned by physicians, four questionnaires were not properly completed 
(less than 15% of the questions were answered), and hence only 100 questionnaires with 
answers were considered. The response rate was 85%. Name, age and gender of the 
physicians were provided as optional questions in order to achieve a satisfactory response 
rate. However, the questionnaire was distributed amongst physicians aged between 30-40, 
and all physicians were required to have managed hypertensive cases for a minimum of 5 
and a  maximum of 10 years.  
 
5.2 Results 
All physicians treated both old and new hypertensive cases in their practice, and Tables 5.1 

















      Legend: * approximately 
 
Table.5.2. Number of older hypertensive cases seen by physicians 
Number of 
Physicians 




        Legend: *approximately 
 





Table 5.3 Distribution of Hypertensive cases seen by Physicians  (Hypertension according 
to JNC 7 criteria) 
No. Category  Percentage 
1 Pre HTN 30 – 35 
2 Stage – I 30 – 35 
3 Stage – II 30 – 40 
Legend: JNC 7 -  Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (197) 
 
10% of physicians have seen and reviewed few cases of hypertensive emergency and 
urgency, and unfortunately 3 patients were aged less than 30 years. More than 75% of 
physicians do not routinely check the blood pressure of individuals visiting  the clinic for 
one or other clinical problems. Furthermore, the time spent by physicians whilst evaluating 
their patients is an important factor for the clinical outcome in disease management. Table 










Table 5.4 Time spent with hypertensive cases by physicians 
Time in 
minutes  
First visit  Therapy 
titration  
Revisit 
Less than 5 ---- 10 39 
5 – 9 57 43 49 
10 – 14 24 47 22 
15 and more  19 -- -- 
Total number 
of physicians 
100 100 100  
 
As noted, the majority of the physicians spent less than 10 minutes during appointments 
with their patients. None of the physicians responding were reviewed via the guidelines 
available for the management of hypertensive patients. Physicians reported that 
approximately 15 to 20% of their patients were only on diet control for hypertension, and 
about 25% of them had one or other end organ damage. None of the physicians referred 
their patients with resistant hypertension for a specialist opinion (198). Most physicians 
start their patients on monotherapy for new hypertensive cases (Table 5.5), and their 
choices of preferred drug vary as listed in Table 5.6. Table 5.7 indicates the preferred drugs 
of choice by physicians for switching to/or adding other drugs for one or further reasons 
such as inadequate control of blood pressure, resistant hypertension, failure of 
monotherapy, and the occurrence of side-effects.  
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Less than 15 52 
15 – 24 48 
Total  100 
 
Table 5.6. Preferred first drug of choice for uncomplicated hypertension by physicians, if 
already on monotherapy 
Name of the drug  Number 
of 
Physicians  
















Table 5.7. Preferred drug of choice by physician without end organ damage/co-existing 






ACE  inhibitors 35 
ARBs  67 




Loop  diuretics  19 
Thiazide  49 
Aldosterone antagonist  13 
Alpha blockers 22 
Vasodilators  19 
Legend: *Number overlapping with each other, ARB – angiotensin receptor blocker, ACE 
inhibitors – angiotensin converting enzyme inhibitors 
 
For monotherapy, most physicians prefer diuretics and calcium channel blockers for 
hypertension regardless of the age group. For combination therapies or switching over to 
other drugs, calcium channel blockers and ARBs are most commonly prescribed. 
Physicians reported that an average of 10 to 15% of their patients discontinued treatment 
by themselves. In about 15 to 25% of the patients, physicians switched the drug therapy. 
There are number of reasons for this occurrence which are listed in Table 5.8.   
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Table 5.8. Reasons for switch-over of the anti-hypertensive drugs prescribed by   
physicians 
Reasons  Number of 
physicians*  
Inadequate BP control  49 
Side effects  58 
Availability of newer / better 
compounds  
56 
Interaction with other drugs  09 
Cost of medicine  12 
Non availability in market  05 
            Legend: *Number overlapping with each other; BP – blood pressure 
 
Inadequate blood pressure control, side-effects and the availability of newer therapeutic 
compounds are the most common influencing reasons for physicians choice to switch over 
to other drugs. Also, from clinical practice, side-effects ascribable to the drugs 
administered  are the most important and common complaint amongst patients, which may 
lead to poor compliance and hence inadequate disease control. Therefore, it is very 
important for healthcare professionals to enquire about the adverse/side-effects of the 
treatment. From the physicians viewpoint, the adverse/side-effects observed for each class 




             Table 5.9. Adverse/side-effects for each major class 
Anti hypertensive agents  Percentage developed 
side effects  
ACE  inhibitors 35 
ARBs  5 
Beta blockers 10 
Calcium channel blockers 5 
Loop  diuretics  12 
Thiazide  10 
Aldosterone antagonist  5 
Alpha blockers 5 
Vasodilators  5 
      Legend: ARB – angiotensin receptor blocker; ACE – angiotensin converting enzyme 
 
From our observations from physicians, it should be noted that ACE inhibitors cause side-
effects in the majority of the patients. Hence, most physicians prefer ARBs rather than 
ACE inhibitors for combined therapy/switching over to other drugs, without even 
attempting to employ ACE inhibitors (Table 5.7). The most common side-effect observed 
with ACE inhibitors is dry cough, and Table 5.10 indicates the most common side-effects 
observed with anti-hypertensive drugs.  
 
Table 5.10. Prominent adverse effects observed with anti-hypertensive drugs by responding 
physicians 
Adverse effects  Physicians 
reported*  
Dry cough  37 
Wheezing  24 
Oedema legs  13  
Palpitation  24 
Giddiness  17 
Gynaecomastia  2 
Weakness  24 
Muscle cramps  12 
Constipation  04  




There are multiple ways to manage these side-effects which all depend on clinical 
circumstances such as seriousness of the side-effect, clinical condition, the patient’s 
tolerability, understanding and awareness. In most clinical scenarios, physicians prefer 
switching over to other drugs in view of the availability of other classes of drug, an 
inability to counsel/convince the patient, and/or for better compliance. The responding 
physicians’ choices in such instances are provided in Table 5.11. 
  
Table.5.11. Physician’s choice when side-effects are noticed with particular anti-  
hypertensive drugs 
Choice  Physicians 
reported*  
Dose reduction  39 
Switching over  75 
Investigations  13 
Addition of another drug 07 
Convince the patient  05  
To analyse the 
interactions 
01 
          Legend: *Number overlapping with each other; 
    
As a commonly-encountered action, most physicians prefer switching to other drugs rather 
than advising a dose reduction. Also, most of them do not attempt to counsel their patients 
and investigate the reasons for side-effects such as drug interactions or co-existing 
illnesses. In the survey, 39% of physicians tried to reduce the drug dose as one of the 
measures. Although it is considered as an improved option, it carries the risk of inadequate 
blood pressure control. Table 5.12 indicates the preferred drug choices made by physicians 
when patients experience such side-effects.               
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Table 5.12. Preferred drug by Physicians when patient had adverse effects 
Class of drugs  Physicians reported*  
ARBs 37 
Calcium channel blockers  23 
Alpha blockers  12 
 Legend: *Number overlapping with each other; ARB – angiotensin receptor blocker 
 
Overall, awareness regarding hypertension and its treatment amongst the general public is 
still far from a satisfactory level of acceptance. Hence, we requested information from the 
responding physicians concerning the reasons for poor compliance, and also barriers for 













Table.5.13. Reasons for poor compliance, (numbers reported /100) and barriers for 
physicians in the management of hypertension 
 
Reasons  Physicians reported * 
BP Controlled  17 
Forgotten to buy 25 
No symptoms  17 
No belief in medicines  09 
No support from family 16 
Non supply of medicines  24 
Want of money  12 
Religious  as reasons  09 
Travel  15 
Missed tablets  24 
Bed effects of drug 21 
Cost of medicines  34 
Switch over to other system of 
medicines  
14 
Neighbour’s influences  04 
Punish family members  12 
Missed prescription  07 
Multiple drugs  10  
Lack of awareness among patients 100 
Legend: *Number overlapping with each other.  
 
There are many possible reasons for the poor compliance as listed in the Table 5.13. 
However, the main factor is lack of awareness amongst patients and the general public 
regarding control, treatment and the complications of hypertension. Of course, this can be 
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achieved through physician-patient interaction, patient education and motivation. There are 
few recommendations suggested by the responding physicians for the improvement of 
patient treatment compliance (Table 5.14). It is therefore very important that physicians 
should provide details regarding the complications of hypertension through physician-
patient interactions, since many patients are unaware of the complications of hypertension 
(Table 5.15).  
 
Table.5.14. Suggestions to improve compliance  
Suggestions  Physicians 
responding*  
Physician-patient  interaction  90 
Patient-to-patient interaction  37 
Interaction with care givers  45 
Patient education  65 
Dosage simplification  76 
Singe tablet / day  44 
Legend: *Number overlapping with each other 
 
Table.5.15. Frequency of end organ damage amongst patients of the responding physicians 
End organ damage  Frequency (%)* 
Coronary artery diseases  25 to 45 
Stroke  15 to 25 
Chronic kidney failure  12 to 20 




Although pharmacotherapy remains the standard treatment for hypertension, diet and 
lifestyle modifications remain an essential need for hypertensive patients. Many patients on 
pharmacotherapy may not have adequate control of blood pressure if weight reductions and 
diet modifications (especially salt reduction) have not been considered. These are common 
issues in such patients (Table 5.16).   
 
Table.5.16. Common issues in the management of hypertensive patient 
 









Diet counselling  84 0 
Weight reduction  69 21 
Salt restriction 100 41 
Regular medication  100 78 
Life style changes  100 9 
Legend: *Number overlapping with each other 
 
In this study, only 15% of physicians conducted a hypertension awareness or counseling 
programme, and unfortunately less than 15% of patient population attended awareness or 
counseling sessions. None of the physicians referred their patients to a dietician, even for 
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patients who were overweight or had obesity problems, together with resistant 
hypertension. Only 14% of the physicians standardised the sphygmomanometer or checked 
the blood pressure apparatus for errors, and 42% of the physicians are familiar with the 
zero error term in sphygmomanometer use. None of the physicians were aware of the exact 
size of blood pressure cuff (Table 5.17); an inappropriate cuff size significantly influences 
blood pressure readings.  
 
Table.5.17. Physician’s knowledge of blood pressure cuff size 
Blood pressure cuff for  Physician answer 
 Yes No 
Infants  -- 100 
Paediatrics  --- 100 
Normal adult --- 100 
Overweight/obese --- 100 
Formulae to calculate cuff size  --- 100 
 
In the questionnaire, we have provided a column for open-ended suggestions for physicians 
to mention any other information related to hypertension and its management. Table 5.18 





Table.5.18.  Further information related to hypertension provided by responding physicians 
 
Response status  Physicians 
responding* 
Hypertension is increasing  67 






Bad life styles  27 
Provide free treatment at all places  17 
Requirement for hypertension 
guidelines 
100 
Challenges for hypertension 
management 
23 
Legend: *Number overlap each other 
 
Among responders, only 7% of the physicians had attended previous training or seminars 
in hypertension. Most of the physicians are interested in attending seminars in hypertension 
management. Moreover, approximately 80% of the physicians are not well aware of the 
hypertension management guidelines. Therefore, we have assessed the physicians needs 
and demands in the particular aspects of hypertension, and these are tabulated in Table 
5.19. I have scored this requirement from 0 to 100 %, with 0 being the least and 100% the 
most important. I have also requested that physicians write their needs in different areas of 
learning in hypertension as noted in the Table 5.19 (first column – areas of 
interest/learning).  
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1.Historical        
    aspects 
0  95 0  0  0  0  0  0  0  0  5 
2.Epidemiology 0  95 0 0  0  0  0  0  0  0  5 
3.Symptoms 0  0  10 3 0  0  0  0  0  0  87 
4.Signs 0  0  9 4 0  0  0  0  0  0  87 
5.Clinical 
evaluation 
0  0  5 5 0  0  0  0  0  0  90 
6.Investigation  0  0  0  0  0  0  0  0  0  0  100 
7.Assessment  0  0  0  0  0  0  0  0  0  0  100 
8.Drugs used in 
practice and 
future 
0  0  0  0  0  0  0  0  0  0  100 
9.Adverse 
effects of drugs 
0  0  0  0  0  0  0  0  0  0  100 
10.  Course and 
complications 
0  0  0  0  0  0  0  0  0  0  100 
11.Audit – how 
to check records 
0  15 12 11 5 9 14 17 10 5 2 
12. Issues in 
pregnancy & 
lactation 
0  0  0  0  0  0  0  0  0  0  100 
13. Follow up 0  0  0  0  0  0  0  0  0  0  100 
14. Prevention 0  0  0  0  0  0  0  0  0  0  100 
15. Traditional 
practices used 
0  25 0  0  0  0  0  0  17 0 58 
16. Alternative 
medicines  
0  17 0  0  43 0  0  21 0  0  19 
17.Socioecono-
mic aspects 
0  13 0  0  0  0  0  0  60 17 10 
18. Yoga / 
meditation  
0  0  0  0  1 0 9 0  0  0  90 
19. Legal issues 0  0  0  0  0  0  0  0  0  4 96 
20. Patient 
education 





0 0 0 0 0 0 0 0 0 0 100 
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Legend: % - percentage; HTN – hypertension, in the above table, the percentage indicates 
the priority/rank, with 0% as least important, and 100% as most important. The numbers 
given inside indicates the number of physicians responding. 
 
From the above Table, it should be noted that most physicians require training in the 
management and preventative aspects of hypertension. Indeed, all physicians mandate the 
need for standard local guidelines for hypertension. The majority of the responders are not 
interested in audit; however, audit represents an essential component of clinical governance 
which provides an insight into the errors made, and also suggestions to improve the 
standard of care.  
 
5.3. Discussion 
Early and prompt diagnosis of the hypertension is mandatory in view of the  asymptomatic 
nature of the disease, and also potential complications arising if left  untreated. From the 
above observations, we conclude that KABP towards blood pressure management amongst 
the physicians was sub-optimal, a similar observation to that made in our previous 
observations amongst interns, together with those from a series of additional previous 
studies(21, 198-202).  
 
The United States Preventive Services Task Force (USPSTF) advises physicians to screen 
individuals aged 18 and above for hypertension. Indeed, there are many factors associated 
with the patients which lead to poor compliance and most importantly, as suggested by all 
physicians, was a lack of awareness about hypertension amongst the patients themselves 
(199). Physicians play a key role in educating patients about the disease; however, in this 
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study, less than 15% of patients conducted such an awareness programme (199). Moreover, 
most of the patients are not interested in attending such an awareness programme. 
Furthermore, another important issue is that regarding self-medication amongst the 
patients. Hence, clinicians need to stress the importance of medications and their associated 
side-effects.  
 
The cost and affordability of the medications prescribed influence the compliance of 
patients. Indeed, there are many barriers for the physicians involved concerning for the 
management of hypertension, and these are discussed in the results section and its 
associated tables. The leading factors are lack of awareness regarding the disease and its 
development,  and also financial implications as previously noted by Wang (203).  The 
physician’s approach towards the non-pharmacological management of hypertension, such 
as lifestyle modification, dietary advice and weight reduction, needs to be strengthened. 
Unfortunately, most of the patients prefer a non-pharmacological approach, which is 
currently unavailable (203). Furthermore, a lack of knowledge of hypertension guidelines 
amongst physicians remains as a further barrier for the management of this condition (204).  
 
Drugs such as diuretics and beta blockers are recommended as the first-line drugs in 
uncomplicated hypertension (197).  ACE inhibitors and calcium channel blockers are 
useful in managing hypertension with associated co-morbidities such as chronic kidney 
disease, angina, etc. (197), or for combination therapies. Moreover, ACE inhibitors and 
calcium channel blockers are more expensive than diuretics, and thiazide diuretics are 
effective in uncomplicated hypertension cases(205, 206). However, the use of drugs of 
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choice for hypertension varies from country to country, and also depends on the 
physician’s specialty (207). In addition, there are variations in the clinical practice amongst 
physicians for managing hypertension within the country, even for regions with standard 
guidelines available (208). In this study, all physicians are internist. However, Mosca et. 
al., demonstrated variations in the pharmacological management of hypertension between 
primary care physicians, obstetricians and cardiologists (207). Most of the cardiologists 
preferred to prescribe ACE inhibitors, beta- blockers and calcium channel blockers, since 
these drugs have proven benefit in cardiovascular health (207). Moreover, cardiologists 
urged the importance of lifestyle modifications, and also encouraged the patients for self-
medications more so than other specialists (207), and most cardiologists are aware of 
recommendations made by  hypertension management guidelines(203).  
 
Italian primary care physicians prefer ACE inhibitors and calcium channel blockers; 
however, diuretics and beta-blockers are preferred more in England. These variations are 
ascribable to variations in practice and guidelines available worldwide (201). In Ireland, 
despite good access to ambulatory blood pressure monitor (ABPM), an invaluable clinical 
tool, the use of ABPM in hypertension management is not encouraged because of lack of 
time, cost and remuneration as noted by General Practitioners (GP) (209). A survey 
conducted amongst general practitioners in Sweden showed that GPs accept higher blood 
pressure levels than those recommended in their guidelines, and elderly patient populations 
appears to serve as a barrier to them, preventing their initiation of drug therapy (210). A 
low prevalence rate of hypertension amongst the Saudi Arabian population has prompted 
physicians to adhere to local clinical guidelines for hypertension management (211). Few 
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physicians measured blood pressure appropriately, and the correct diagnosis of 
hypertension was not established in many patients. Moreover, regular checks of blood 
pressure performed in all clinic patients have not been encountered. Additionally, one or 
more items such as clinical examination, investigations and the prescription of optimal 
drugs of choice have been missed in many patients (211). Eastman noted that hypertension 
is the most common problem in Australia; however, it remains untreated in view of a lack 
of clarity and consistency in the evidence-based guidelines available for hypertension 
management (212). A large  number of patients had never checked their blood pressure 
within last 12 months preceding the survey, although they had the opportunity to visit 
physicians (213). Patients and physicians prefer medications with the fewest side-effects 
for reasons of better compliance (201). Unfortunately, physicians lack the knowledge made 
available by specific guidelines (214). More appropriate use of the drugs which consider all 
possible clinical aspects (including clinical situations and affordability to the patients) is 
mandatory since this predicts the effective compliance of the patients (200).   
 
Most of the patients diagnosed with hypertension received pharmacotherapy (201). In our 
observations, physicians mentioned that most of their patients required a switch in drug 
therapy in view of one or more of the reasons noted above (215); however, in further 
reports, only a limited number of patients were required to switch drug therapies (201, 
216). The major reason for this switch is inadequate control of blood pressure as observed 
in this study (217). It is therefore very important for the physicians to monitor the response 
and side-effects of the drugs in patients who are all on pharmacotherapy. Ambrosioni et. al. 
documented that physicians reported that about 10 to 20% of their patients had side-effects 
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with medications, although 69% of them reported such side-effects arising from the use of 
these drugs. Furthermore, physicians are not aiming to achieve the target blood pressure in 
their patients (198). This huge variation may be attributable to a lack of close observation 
of symptoms. As with previous studies performed, even in our study physicians failed to 
spend sufficient  time with patients in their first and subsequent visits (198, 201). Many 
physicians emphasised the importance of patient education and awareness. However, short 
clinical encounters with patients renders it much more difficult for physicians to educate 
the patient during their visit (198). Thus, the lack of a physician’s instructions to the 
patients regarding disease management and their associated complications and 
administered drug side-effects lead to poor patient compliance, a phenomenon which gives 
rise to the many complications noted (of a reversible or irreversible nature).  
 
5.3.1.Demands for Physicians in hypertension management learning 
Most of the physicians are required to attend appropriate training courses or seminars for 
hypertension management (202). Further exploration of the learning aspects of 
hypertension revealed that many of them are interested in learning the clinical management 
and prevention of hypertension rather than the historical aspects and epidemiology. Also, 
many of them did not focus on clinical audit (which represents an essential part of clinical 
governance) in order to promote and maintain the standard of care.   
 
In a previous study, it has been demonstrated that physicians working in academic centres 
with elements of teaching and assessment, and also dedicated settings for hypertension 
control and management have higher performance rates than  physicians in general or the 
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private health care centres (202). This indicates the major requirement for continuing 
education for disease management to produce an improved standard of care. As observed 
in this study, physicians clearly underestimate the challenges of hypertension management 
(218).  
 
Cuspidi et. al. conducted a study which explored primary care physicians’ approach 
towards hypertension management (219). Interestingly, they made two new observations: 
(i) physician’s age and duration of the practice inversely related to the knowledge of 
guidelines, and (ii) an adequate blood pressure control achieved by many doctors probably 
reflected their own skills, and is inversely related to guideline knowledge (219). This urges 
the importance of intensive professional education and training through continuing medical 
education, and particularly for physicians with a longer duration of practice (219). A 
similar observation, along with diminished knowledge guidelines amongst rural physicians 
was noted amongst Polish primary care physicians (204). Therefore, the investigator 
hypothesize a fact from the above observations, specifically that the greater the age and 
longer the duration of practice of physicians, the busier they are with their clinical practice. 
Hence, they may have little or no time to read and review the latest guidelines, or to attend 
any seminars. Also, access for rural physicians to attend relevant training programmes or to 
access materials is complicated (204).  
 
5.3.2.Medical Education and Training 
As noted previously, KABP amongst interns was sub-optimal, an observation which was 
consistent with studies from developed and developing nations (21, 90-92). A study 
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conducted in Jordan revealed that junior doctors (who were recent graduates) lack the 
clarity in hypertension management which was characteristic of their  seniors(220). This is 
probably ascribable to a lack of training in these aspects during medical education (90).  In 
addition, the above observations strongly emphasise the requirements for continuous 
update in medical curricula for medical students, and medical schools should include 
programmes on the quality control of medical devices (blood pressure apparatus) and the 
management of hypertension (21).  
 
5.3.3.Requirement for local guidelines 
There is urgent requirement for local guidelines in managing hypertension (221). Indeed, 
guidelines need to focus on the clinical, social and economical aspects of  patients. 
Moreover, it should focus on ease of access, availability and administration (221). Hence, 
the Ministry of Health should implement nationally agreed guidelines by taking all aspects 
into consideration for the better control of disease and compliance.  
 
5.4.Conclusion 
Overall, KABP towards hypertension guidelines and management amongst physicians was 
found to be sub-optimal. There are many barriers for physicians to treat their patients for 
improvements in health care. All physicians should be encouraged to monitor blood 
pressure as a routine check for all of their patients, a development which will help us 
diagnose the disease earlier.  
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The Ministry of health or national societies should emphasise the need for training, and 
also promote training through continuing medical education. There is also a major 
requirement for local guidelines for the treatment and management of hypertension. 
However, guidelines should be designed according to clinical as well as socio-economic 
aspects of the patients and should be cost-effective. Moreover, all doctors at primary care 
level should be educated regarding hypertension management. Promotion of evidence-
based medicine and curriculum is mandatory in order to bridge the gap in knowledge of the 
physicians involved in the management of  such chronic diseases.  
 
5.5. Limitations of the study 
A relatively small dataset was employed, physicians from same region were selected 
(urban and the same Indian city), and the same specialty was involved: these represent the 
limitations. Further studies with a larger dataset focused on comparing the knowledge 
acquired amongst physicians of differing specialties and locations (i.e., urban versus rural) 











CHAPTER 6. AWARENESS OF HYPERTENSION AMONGST THE GENERAL 
PUBLIC 
6.1. Methodology 
A Questionnaire survey was conducted amongst 100 hypertensive patients after briefing 
the participants on its completion. The questionnaire was provided to the patients in their 
local language (Tamil), since they did not understand English. The response rate was 
100%, and there were 54 males and 46 females in our study group; 30 patients were from 
urban areas and the remainder were from rural areas. The patients’ educational status was 
categorized according to the  modified Kuppuswamy’s scale (222).  All of the patients 
recruited to the study group were diagnosed with hypertension for at least 5 and a 
maximum of 39 months.  
 
6.2. Results 
The age group of our patients varied from 35 to 64 with (mean age 46.5 years). Their 
demographic, educational status and domicile are provided in Tables 6.1 and 6.2. In our 








Table 6.1. Demographic pattern of the survey patient participants 
Gender and Age Group 
Age in years Male Female Total 
35 – 44 18 15 33 
45 – 54 24 22 46 
55 – 64 12 09 21 
Total 54 46 100 
 
Table 6.2. Educational status and residence location of the patient participants 
Educational status Domicile 
Literate Illiterate Urban Rural 
Male Female Male Female Male Female Male Female 
48 28 06 18 12 18 42 28 
76 24 30 70 
100 100 
 
I have included only hypertensive patients. Also, all of these were diagnosed with 
hypertension for at least 5 and a maximum of 39 months. I have also provided the number 





Table 6.3. Duration of hypertension treatment for the patient participants 
Duration of medication for hypertension  
Duration in months  Male Female Total 
5 – 9 13 05 18 
10 – 19 10 11 21 
20 – 29 17 19 36 
30 – 39 14 11 25 
40 and above 0 0 0 
 54 46 100 
 
All the patients were requested to mention the name of prescribed medicines in the form. 
Also, I have tabulated the answers and their association with educational status (Table 6.4).  
Table 6.4. Patients awareness of the name of prescribed medicines 
Number of patients aware of the names of prescribed medicines 
Yes No 
Literate Illiterate Literate Illiterate 




From the above table, it is clear that more than 50% of the patients did not remember the 
names of medicines that they were prescribed. On further analysis, 52% (39 out of 76) 
literates and 66% illiterates (16 out of 24) were unaware of their medication’s names. This 
indicates that awareness status is sub-optimal amongst our patients, regardless of their 
educational status. Amongst 100 patients, clinicians checked the blood pressure in 92 
patients, and nurses checked these parameters for the remainder.  In India, doctors usually 
check the blood pressure since the sphygmomanometer is still in frequent use. The use of 
an automatic blood pressure monitor in India is not frequently encountered. None of the 
patients had blood a personal blood pressure monitoring device at home, and none of them 
were aware of usage of such devices.  Table 6.5 demonstrates the participants’ time of 
recent blood pressure checks.  
 
Table 6.5. Recent (last) blood pressure check by the patients 
Recent Blood pressure check 
Duration in months Male Female Total 
Less than 3 24 17 31 
3 – 5 04 13 17 
5 – 8 17 09 26 
More than 8 09 07 26 





 of the patients had their blood pressure checked within the last 3 months. This 
status may not be appropriate, since some patients who may check their blood pressure 
routinely did not get their blood pressure check performed recently in view of one or more 
personal issues such as socio-economic problems, clinic visits and time factors. In order to 
acquire appropriate data, we have requested that our patients provide information regarding 
how often they have their blood pressure checked in the questionnaire. The majority of the 
patients did not answer that question and hence we were not able to provide data for it.  
 
Table 6.6. Status of disease control in patient participants 
Status of blood pressure control 
Under control Not under control 
Male Female Male Female 




From the above Table, it should be noted that only 63% of patients had their blood pressure 
under control with medicines, whilst the remainder of them did not have adequate blood 
pressure control. Indeed, many of them discontinued  treatments for hypertension. Only 12 
patients (8 males and 4 females) amongst 100 patients had good compliance with treatment 
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for hypertension. There are multiple reasons listed by them for the discontinuation of 
treatment (tabulated in the Table 6.7). 
 
Table 6.7.  Reasons for discontinuing treatment(s) for hypertension 
 
Reasons for discontinuing the treatment for hypertension 






Blood pressure controlled 07 03 10 
Forgotten to buy 02 06 08 
No symptoms 
 
01 13 14 
No belief in blood pressure reading 05 03 08 
No support from family 09 07 16 
No medicine in the hospital 07 04 11 
Due to financial constraints 09 01 10 
Multiple reasons (2 or more reasons from the 
above) 
06 05 11 
Less information from physician 36 30 66 
Less physician – patient interaction 40 38 78 
No or low confidence in the hypertension 
treatment or physicians 
25 28 53 
Legend: *numbers overlapping each other  
 
Although there are multiple reasons for this, including the socio-economic issues listed, the 
most common problems are poor physician-patient interactions, inadequate information 
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regarding the disease and its management from physicians, and a generalized lack of 
confidence either with treatment or physicians. This problem exists not only in India, but 
elsewhere. Hence, patient counselling/education and an enhanced level of physician-patient 
interactions are vital measures required in order to overcome such issues. Interestingly, 
many patients tried to obtain information regarding hypertension from other sources (as 
listed in the Table 6.8).     
Table 6.8. Information obtained by patients participants regarding  hypertension 
Information about hypertension 
Information obtained through Male* Female* Total* 
Pictures/posters 12 03 15 
Television 29 17 46 
Radio 11 04 15 
Books 03 01 04 
Newspaper 14 02 16 
Advertisement 09 01 10 
Doctors and nurses 50 37 87 
None (never obtained information from 
anything) 
 
04 09 13 
Legend: *number overlap each other 
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Healthcare professionals serve as the major narrators regarding health and disease. Indeed, 
although most of our patients obtained information through them,  still lacking was 
information concerning adequate disease control. Therefore, the information obtained was 
probably of a superficial nature. Additionally, media is the most important messenger for 
delivering information about health and disease. Hence, there is a need to monitor, regulate 
and standardise the information delivered via this route. Many patients in our study group 
were aware of the non-pharmacological methods for hypertension control, and some of 
them have been adapted to control blood pressure. Tables 6.9 and 6.10 list the non-















Table 6.9. Non-pharmacological methods adopted by patients for hypertension control and 
monitoring 
Methods adapted to reduce/control blood pressure 
Methods adapted Male* Female* Total* 
Weight reduction 21 14 35 
Salt reduction 37 18 55 
Diet reduction/change 17 19 36 
Smoking cessation 19 00 19 
Stop alcohol drinking 22 00 22 
Physical activities/exercise 19 11 30 
Regular blood pressure check-up and 
medication adjustment/titration 
39 28 67 
A combination of these 47 34 81 







Table 6.10. Awareness amongst the patient participants regarding diet and lifestyle 
modifications available for the control of hypertension  
 
Awareness amongst the public regarding diet/lifestyle modifications  for hypertension 
Diet or lifestyle Male* Female* Total* 
Food with low salt 02 00 02 
Food with high salt 34 12 46 
Food with excess fat 24 11 35 
High fibre diet 09 04 13 
Eating green vegetables and green 36 13 49 
Excessive water intake 17 09 26 
Stop non-vegetarian food  27 14 41 
No idea 05 03 08 
Legend: *numbers overlap with each other 
In India, alternative medicine is one of the common medical practices for the management 
of many diseases, including hypertension. Iindeed, alternative medicine is emerging 
throughout the world. There are some lifestyle modifications along with alternative 
therapy/methods practiced for hypertension management. The alternative methods adopted 
by our study patients for hypertension management are listed in Table 6.11.  
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Table 6.11. Alternative methods to reduce blood pressure in hypertension adopted by 
patient participants 
Alternative ways to reduce blood pressure 
Methods adapted Male* Female* Total* 
Peace of mind 17 04 21 
Avoid anger 36 21 57 
Avoid stress 25 19 44 
Yoga practice 17 04 21 
Meditation 09 03 12 
Eating fish 04 01 05 
Prayers 26 27 53 
Talking loudly 19 11 30 
Avoid  lifting heavy materials 15 09 24 
No idea  04 03 07 
Legend: *number overlap each other 
 
Complications of hypertension include micro- and macrovascular damage. Unfortunately, 
the majority of the patients recruited to the study were not aware of the all the serious 




Table 6.12. Patients’ awareness of complications arising from hypertension 
Awareness of complications of hypertension 
Complications Male* Female* Total* 
Myocardial infarction 23 12 35 
Stroke 24 13 37 
Bleeding in the brain 14 02 16 
Renal failure 11 03 14 
Damage to blood vessels 09 01 10 
Heart failure 13 04 17 
Not known 04 09 13 
Legend: *number overlap each other 
 
There are some views regarding hypertension amongst the general public which include 
that it is (1) a disease of the rich, (2) a preventable disease, together with many others as 
listed in the Table 6.13. Some of them have mentioned alternative medicine as the best 
treatment option for hypertension. Such views are obtained through old local language 
literatures, social conversations, their own personal or family or friends experiences, and 




Table 6.13. Opinions on hypertension 
Public opinion on hypertension 
Opinion Male* Female* Total* 
Disease of rich 17 14 31 
Preventable disease 09 04 13 
Long-term treatment 19 13 32 
Alternative medicine is the best 13 04 17 
Familial 12 04 16 
Serious disease 07 01 08 
No comments 22 19 41 
Legend: *number overlap each other 
 
6.3. Discussion 
In India, the prevalence of hypertension is high (Figure 1.1) and there is a concern for 
further rapid escalations in the prevalence of this condition with regard to economic 
development, industrialisation, globalisation and diet/lifestyle changes amongst the 
population (223). However, the awareness, treatment and control of hypertension amongst 
the general public are extremely low as observed in this study, which has been 
demonstrated previously (100).  Furthermore, there is also a substantial disparity between 
the prevalence, awareness, treatment and adequate control of blood pressure amongst the 
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patients of developing and developed nations, and also between genders (15, 224). This is 
illustrated in Figure 1.3(15).   
 
Cardiovascular disease is currently the leading cause for mortality worldwide, and 
especially amongst the Asian population (4, 225). Indians are at more risk of 
cardiovascular disease, regardless of whether they live in their native lands or overseas 
(225, 226).  Hypertension is one of the major risk factors for mortality within the Indian 
population (4).  Excessive salt intake, alcohol consumption and obesity are the major risk 
factors (226). Indeed, the mean salt intake is 8.5 grams per day amongst Indians, which is 
markedly higher than the recommended level (227).   
 
In this study, 63% of the patients had their blood pressure adequately controlled which is 
still lower than the expected target(100). Unfortunately, there is no huge variation among 
illiterate and literate, and males and females. Our patients have little knowledge about the 
importance of adequate control of blood pressure(15, 227) and awareness of complications 
of hypertension(15).  Hypertension is asymptomatic and the measurement of blood 
pressure is considered as a secondary task by physicians and not routinely employed. 
Hence, the early diagnosis of hypertension is often overlooked (15). Even for patients 
receiving treatment for hypertension, there are many reasons for discontinuing the 
treatment which are listed in Table 6.7. Most common factors are poor awareness, 
economical burden, the non-availability of drugs, and poor patient-physician interactions 
(15). Also, treatment guidelines often do not meet the requirements of patients (15).  
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Overall, awareness regarding hypertension amongst patients is low, which has been 
persistently  and previously reported in the literature (15, 16, 221, 224, 228-230). However, 
no significant variations between males and females, nor those between rural and urban 
populations, were observed. This observation may, however, be ascribable to the relatively 
small sample size (n = 100). There are many studies reported in the literature performed on 
the Indian population which have demonstrated that the awareness and control rate of 
hypertension in urban populations is significantly higher than that in rural Indians (12, 16, 
99). Potential explanations for this variation could are the relative levels of knowledge, 
access and availability of  treatments (12). However, there are some other studies 
conducted amongst Indians living overseas which have proven that awareness amongst 
them was still lacking (231). Unfortunately, many patients were not aware of the serious 
complications involved (232, 233).   
 
As noted from the observations made here, though there may be small  variations regarding 
hypertension control reports between patients and physicians, the factors responsible for 
the poor levels of compliance reported by both are similar. Poor patient-physician 
interactions or relationships are amongst the potential causes for poor compliance (231). 
Hence, we are aware of what is lacking to achieve adequate disease control; however, 
further work is required towards that goal in order to improve the standard of care.  
 
In the PatenT study conducted amongst hypertensive populations in 2003, the prevalence 
of hypertension was greater in women than men (97). Awareness of the hypertension status 
amongst the subject group was low, and most of the patients involved had never checked 
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their blood pressure (the majority of hypertensive patients had inadequate blood pressure 
control). Interestingly, in this study there was no significant blood pressure difference in 
the hypertensive patients between the patients who were on pharmacological and non-
pharmacological treatments for hypertension (97). The rate of treatment for hypertension 
and the rate of control of hypertension in Turkey, England, Egypt and USA were 78%, 
68%, 60% and 85%, respectively, and 8%, 9%, 8% and 34%, respectively. These results 
concur with many other survey reports(16, 97).  
 
However, successful initiatives for the management of chronic disease have been 
performed in a number of developing countries. Indeed, a strong family doctor-based 
system in Cuba has led to active and early diagnosis, and resulted in significant reductions 
in the prevalence of cardiovascular diseases; the Cuban healthcare system has the highest 
rate of controlled hypertension in the world (234). Healthcare workers and community 
leaders should be trained to promote awareness, and also diagnosis of the disease at an 
early stage-such participation has been described as successful in many developing 
countries(235-238). Media and usage of communication devices such as mobile phones 
and internet services are currently increasing in developing countries. The delivery of 
messages through such modes is effective, and these represent improved means of 
controlling chronic diseases such as hypertension and diabetes (98, 239-241).  In a study 
conducted on the Turkish population in order to evaluate the impact of mass media on 
promoting the awareness of hypertension, there was a significant rise in hypertension 
awareness amongst the public after mass media campaigns (this is illustrated in Figure 6.1) 
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(98).  This campaign was conducted through television, radio, posters, announcements and 
also printed materials (98).  
 
Figure 6.1. Graphical demonstration of the percentages of pre- and post-campaign answers 
based on ‘yes’ and ‘no’ responses amongst hypertensive patients 
 
Legend: Figure copied from Oto etal., (98). Question 1: Do you know your blood pressure 
values?; Question 2: Have you checked your blood pressure within the last 2 months?; 
Question 3: Do you know the optimal blood pressure levels?; Question 4: Do you know the 
complications of hypertension? 
 
6.3.1. Patient Empowerment 
Patient empowerment is a recent outgrowth in the natural health movement. This provides 
the patient with an active role in the decision making processes for their own healthcare. 
Patient empowerment involves patient participation in the awareness programs, 
communications with doctors and other health care providers, patient safety, evidence 
gathering, shared decision making, together with discussions with other patients and many 
others. Empowerment is a multidimensionally complex and contested concept, which 
! 168!
includes a broad social, political, emotional and a emancipatory method (242). Patient 
empowerment measures include the patient activation measure (PAM) and the patient 
empowerment scale (PES)(243). PAM estimates the skill, knowledge and confidence of 
patients in the self-management of health (244). It also predicts patient participation in 
medical encounters, behavioural change, use of quality behaviours and associated data 
therefrom (245). PES evaluates the patient’s perceived risk and benefits of obtaining access 
to health and disease (246).  
 
Most of the hypertension awareness programmes focus on the self-empowerment of 
patients. Hypertension management initiatives conducted in Canada improved the patient’s 
self-empowerment status, and also assisted healthcare providers such as doctors and nurses 
to manage the hypertension effectively (247).  
 
6.4.Conclusion 
A cost-effective public measure to create awareness regarding the prevalence of   
hypertension amongst the general public is mandatory. Awareness programs should 
include the provision of information regarding the prevalence, early diagnosis, treatment, 
control, complications and prevention of this condition, including non-pharmacological 
approaches (diet and lifestyle modification). Ministries of Health or National societies 
should promote this awareness through any means of communication such as media, 
awareness programmes and education at school level (98). Also, there is a major 
requirement for Governments to provide measures for a legally-acceptable unit of salt in 
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the processed food available for consumption, such as that currently available in South 
Africa (248).  
 
A very important consideration regarding disease management in developing countries is 
to provide effective primary healthcare. Hence, we should take initiatives to strengthen the 
awareness amongst all healthcare professionals, including nurses and paramedics (249, 
250). Though most of the basic drugs in India are provided free of cost, governments 
should ensure the continuous supply of these drugs in order to maintain an improved level 
of compliance.  All healthcare workers, including physicians, nurses, pharmacists, 
dieticians, community health and social workers should participate in the control of 
hypertension. Herculean efforts are therefore required to prevent the epidemic rise in  
complications, and also stabilise the financial burden arising from these implications.  
 
6.5.Limitations of the study 
The limitations of this study include a relatively small sample size, together with many 
patients not willing to provide their income, and some also not willing to provide their 
occupational status; hence, socioeconomic status was not assessed. Moreover, all the 










CHAPTER 7: GENERAL DISCUSSION AND FURTHER RESEARCH 
7.1. Reviewing rationale 
Study I : End organ damage in newly detected hypertension 
It was observed that 86% of patients who participated in the study had one or more forms 
of end organ damage ie., microalbuminuria, left ventricular hypertrophy or retinopathy. 
Unfortunately, all of these patients have had their diagnosis of hypertension only at the 
time when their end organ damage was first diagnosed. Multiple aetiologies include lack of 
awareness amongst the general public and physicians not being able to find or exclude 
secondary causes of hypertension.  
 
Study II: Thyroid disorders and hypertension 
We can strongly conclude from study among large number of patients that  hypertension 
(both systolic and diastolic hypertension) is significantly associated with thyroid 
dysfunction. Interestingly, a new observation that mean arterial pressure and ratio of 
systolic to diastolic blood pressure are higher among thyroid disorders.  
 
Study III and IV: Awareness among physicians and public 
Awareness among health care professionals and public is mandatory for managing the 
chronic non-communicable disease such as hypertension. A preliminary step in the disease 
occurrence is the lack of awareness and poor communication. We have noted that 
awareness among public is well below the expected level. Not only that, knowledge, 




7.2. Summary and Findings 
• The confirmation of powerful relationships between hypertension and end organ 
damage (EOD) such as retinopathy, microalbuminuria and left ventricular 
hypertrophy/increased left ventricular mass 
• Since all EODs are interdependent, the presence of one or another of these clinical 
developments mandates the requirement for intensive evaluation  
• In cases of snake-bite (prevalent in India), the possibility of severe hypertension 
requiring oral or intravenous anti hypertensives may be required. 
• Systolic hypertension and systo-diastolic hypertension are common in 
hyperthyroidism and hypothyroidism, respectively 
• Significant associations exist between SBP:DBP ratio, MAP and thyroid disease 
status 
• In India, knowledge, attitude, behaviour and practice towards hypertension and its 
guidelines and management amongst physicians were sub-optimal. These may be 
improved through clinical governance and CME programs.  
• Awareness about hypertension and treatment among general public was well below 
the satisfactory point. This mandates the urgent need to promote such awareness 
through media, campaign and social education. Also, it is worthwhile to re-analyze 





7.3. Implications and importance of the findings 
1. Regular monitoring of blood pressure along with weight and height in all clinics or 
during hospital visits, which will enable to detect the diagnosis of hypertension 
early which in turn prevent the complications 
2. Adequate blood pressure control is needed to prevent end organ damage  
3. Routine screening for end organ damage in all hypertensive patients is essential to 
diagnose end organ damage earlier 
4. Secondary causes of hypertension need to be considered, and also to be implicated 
where appropriate; at least in patients with resistant hypertension, hypertension in 
an unusual age group, severe hypertension, hypertension with end organ damage or 
any other associated signs of secondary causes 
5. Thyroid disorders are common in India, and are increasing in prevalence. Most of 
the thyroid disorders are undiagnosed in India. It is therefore essential to screen the 
patients for thyroid dysfunction in all hypertensive patients or at least with one or 
more of the features suggested 4 above. 
6. It is mandatory to enforce and empower the knowledge and awareness regarding 
hypertension amongst physicians and the general public in order to prevent 
mortality and morbidity associated with hypertension. Also, it is vital to stabilise 
the economic burden for the country. Hence, health authorities should promote 
awareness programs through media or any other modes for the public, and also 




7.4. Further research 
• Initiate the periodic monitoring of blood pressure in all clinics or hospital visits, 
and then assess the prevalence and incidence of hypertension, and hypertension 
with end organ damage, with regard to age, sex, and geographic location (urban or 
rural), and also assess the associated mortality and morbidity rates, and the overall 
cost benefit. Since in our study, we found that newly detected/undiagnosed 
hypertensive patients presented with end organ damage which has further 
implications. 
• Periodic screening of end organ damage in hypertensive patients, including an 
assessment of the mortality and morbidity benefits with regard to cardiovascular 
risk factors amongst the Indian population, is considered vital. In India, currently 
there are no standard guidelines available for the screening of end organ damage in 
hypertensive patients, and most of them have more than one or other risk factor for 
such end organ damage. Hence, such screening processes will serve to diagnose 
these complications at an early stage.  
• Thyroid dysfunctions are increasing in prevalence, and hypertension is commonly 
associated with it. Hence, it is clearly worthwhile to assess the cost effectiveness of 
screening all hypertensive patients for thyroid dysfunction which will enable us to 
prevent complications involved. However, further studies are warranted in order to 
establish the cost-effectiveness of such interventions.  
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• Thyroid function should improve with adequate treatment(s) for particular disorders 
(either hormone replacement or anti-thyroid hormone). However, blood pressure 
will improve in hypertensive thyroid disorder patients, and further studies are 
required to assess, correlate and estimate values of TSH, T4, and T3 with regard to 
blood pressure values and end organ damage in hypertensive patients with thyroid 
dysfunction. Since this will yield more valuable information regarding whether any 
of the thyroid hormones have relationships with prognostic, mortality, morbidity 
and treatment responses for hypertension.  
• Snake bite is a common problem in India; hence, further studies are required 
amongst a larger Indian population in order to establish the relationships between 
blood pressure and snake envenomation, and also the urgent need for early 
treatment. Because catecholamine surge is one of the pathologies which gives rise 
to marked blood pressure elevations and increases mortality, early treatment with 
anti-hypertensive drugs not only controls the blood pressure, but also reduces the 
catecholamine cascade.  
• As noted from this study, physicians KABP are sub-optimal, and most of the 
physicians require training in many aspects of hypertension. Further studies are 
therefore required amongst physicians to study KABP after proper training has 
been given so that their KABP can be evaluated post- training, or respond to desires 
for further training  processes or deficits in the training module delivered; changes 
in the delivery of such training or training modules should also be considered.  
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• Knowledge and awareness amongst the general public regarding hypertension are 
currently lacking. Hence, there is a major requirement to promote the awareness 
program. More importantly, it is important to study their knowledge and awareness 
during both pre- and post-campaign/awareness programmes amongst the Indian 
population, and also to monitor patient activation measures and patient 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix I: QUESTIONNAIRE STUDY AMONG PHYSICIANS ABOUT 
HYPERTENSION MANAGEMENT 
Name (optional):                                                       
Specialty (mandatory):  
Practice location (village/town):   Age (optional):         Sex (optional): 
 
1 How many hypertensive patients have you seen in your practice during the past 12 
months? 
 
2 How many of these were newly diagnosed hypertensive patients? 
 
3 Please give the percentage distribution of your hypertensive patients according JNC VII 
crteria 
Normal (<120/80) -                                                      Pre-hypertension (120-139/80-89)  -    
Stage I (140-159/90-99) -                                            Stage II (>159/99)    - 
 
4 How much time do you spend in seeing a hypertensive patient?  
 
5. Please indicate separately mean time in minutes for 
First visit -                                      Therapy titration visits -                           Follow-up 
visits –  
 
6. How many visits do you do on average during the first 3 months in order to achieve goal 
blood pressure? 
 
7. What proportion of your patients is receiving antihypertensive monotherapy? 
 
8. Prefer the drug of choice for HTN (monotherapy), for patients without any evidence of 
end organ damage/co-existing illness (PLEASE GIVE YOUR ORDER OF PREFERENCE 
like 1,2,3,4,5,6,7,8,9,) 
ACE inhibitor -                             Angiotensin II receptor antagonist -               Beta-
blocker –  
Ca Ch blocker -                            Loop diuretics -                                                  Thiazide 
diuretics -            Aldosterone antagonist –         Alpha blocker -                                                    
Vasodilator –  
Others...................................................................................................................... 
 
9. When monotherapy is unsuccessful, what compound do you preferably add to existing 




10. What percentage of hypertensive patients in your practice had antihypertensive therapy 
discontinued or required switching from an antihypertensive compound to another during 
the past 12 months? 
 
11. How often was therapy discontinuation or switching due to: (please provide %) 
a) inadequate blood pressure lowering; 
b) side effects of the drugs; 
c) availability of newer and better compounds; 
d) interaction of the antihypertensive agent with other concurrent therapies; 
e) other reasons......................................................................................................... 
 
12. Please indicate the percentage incidence of adverse responses to each of the major 
classes of antihypertensive agents, in your patients during the past 12 months. 
 
 
13. Please indicate the predominant type of adverse effect observed in your patients with 
each of the major classes of antihypertensive drugs. 
 
 
14. What is your more frequent choice when side effects are observed? (please provide %) 
a) Dose reduction of the original compound; 
b) switching to another compound; 
c) prescription of laboratory examinations; 
d) addition of another antihypertensive agent aimed at controlling side effects. 
e) others .......................................................................... 
 
15. What is the preferred class of antihypertensive agent you choose when switching from 
a compound of each class because of adverse effects? 
 
16. What do you estimate is the percentage of your hypertensive patients who do not 
comply with your prescriptions? 
 
16 What are the main reasons for patients' poor compliance? (please provide %) 
a) Forgetfulness of prescriptions; 
b) side effects of drugs; 
c) refusal to accept the chronic nature of the disease; 
d) lack of understanding of the importance of long-term continuing treatment; 
e) complexity of the drug regimen. 
f) others .......................................................... 
 
17 Which of the following suggestions do you recommend in order to improve 
compliance? Choose the order of preference like 1,2,3.......... 
a) dosage simplification; 
b) educational interventions and provision of information to the patient; 
c) good physician±patient interaction; 
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d) improved drug efficacy; 
e) improved tolerability profile of drugs; 
f) single-agent therapy. 
g) others....................................................... 
 
18) How many percentage of your hypertensive patients were maintained on diet only? 
 
 












22) Did you conduct any awareness programme on HTN? 
 
 
23) Do you refer your hypertensive patients to dietician?  
 
 
24) What are the common issues in managing the hypertensive patients in your practise? 
 
 
25) Do you subject your sphygmomanometer for standardization or check your 
sphygmomanometer for error? 
Yes ☐    No ☐ 
If yes, how frequently……………. 
 
26) Are you very much familiar with errors of sphygmomanometer device? 
Yes ☐    No ☐ 
If yes, please mention the possible 
errors…………………………………………………………… 
 
27) Please mention the BP cuff size for the following in inches: 
Infant……..     Paediatric ……………….  Normal sized adult…………… Obese 
…………. 




PRACTITIONER’S ATTITUDE TOWARDS THE LEARNING ASPECTS ON 
HYPERTENSION 
Please read everyone and tick appropriate columns as per your need.  
Areas of learning/ 
interest 
0 10 20 30 40 50 60 70 80 90 100 
1.Historical aspects            
2.Epidemiology            
3.Symptoms            
4.Signs            
5.Clinical evaluation            
6.Investigation             
7.Assessment            
8.Drugs used in 
practice and future 
           
9.Adverse effects of 
drugs 
           
10. Course and 
complications 
           
11.Audit             
12. Issues in 
pregnancy &lactation 
           
13. Follow up            
14. Prevention            
15. Traditional 
practices used 
           
16. Alternative 
medicines  
           
17.Socio-economic 
aspects 
           
18. Yoga / meditation             
19. Legal aspects            
20. Patient education            
21. Formulation of 
standard guidelines 
for hypertension 
           
Percentage from 0 to 100 indicates the priority/rank with 0% as least important (not agree) 
and 100% as most important (strongly agree) 
  






















































Appendix II: QUESTIONNAIRE SURVEY AMONG PUBLIC ABOUT THE 
AWARENESS OF HYPERTENSION 
 
Dear friend 
We are conducting a study to find out the awareness of hypertension. As you have high 
blood pressure (BP) we would like to collect some information  on your views related to 
the medication(s) consumed for blood pressure, test carried out and bad effects of 
medicines taken for high blood pressure.  Kindly read each questionnaire / Statement and 
respond to each in the respective column. Your participation is greatly appreciated, as your 
information will help us to plan our educational programmes for practitioners. Your name 
and identity will not revealed to third party members.  
 
  Thank you very much for your valuable participation 
_______________________________________________________________________ 
     
Name  :      Domicile (village /Town)……… 
Age  :      Educational status………… 
Gender:      Record No: OP/ IP ………… 
Date                                     Occupation……………………..Income per month…………. 
No  Questionnaire / statement  Yes  No  Comments  
1. Do you ever had high blood pressure (BP)?. 
If yes, what was your age at the time of diagnosis as high 
blood pressure ( BP) ? Mention here……. 
   
2. Did the Doctor or Nurse tell you that you have high BP?    
3. Are you taking medicines for high BP, if yes?     
4. How long are you taking medicines for high BP -----------
----- years / …..Months  
   
5. Do you still have high BP ?    
6. Kindly mention the name of the tablets taken for high 
BP? …………………………………………………….. 
   
7. When did you check your BP? 
12 month ago ! 
6 month ago    ! 
Kindly let me known the date 
   




What  was the level? Mention if you know……. 
   
9. Do you have BP recording machine at home? 
If yes, Mention the name of the machine……… 
   
10. Do you check BP on your own?    
11. Have you ever stopped taking medicine for high BP?     
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If yes why? 1. Bp is not getting controlled ! 
Forgotten to buy tablets ! 
No symptoms ! 
BP under control ! 
No belief in medicines given for high BP ! 
Any other – specify ! 
12. Are you following any methods to reduce high BP? 
 If yes what methods... 
Weight reduction ! 
Salt reduction ! 
Diet reduction ! 
Smoking ! 
Stop drinking alcohol ! 
Regular BP Checking ! 
Any other specify ! 
   
13. How did you know the effects of about high BP? 
If yes, how?……. 
Through Pictures / posters ! 
Through TV ………………….! 
Through Radio ……………….! 
Through Books ……………….! 
Through News papers ……….! 
Through Advertisement …….! 
Through Doctors / Nurses …….! 
   
14. What type of food reduces high BP? 
Food with low salt ………………….! 
Food with high salt content………. ! 
Food with excessive fat…………… ! 
High Fibre diet………………………! 
Drinking excessive water ………….! 
Vegetables and Greens ……………..! 
Diet / control  
Any other specify 
   
15. What the alternative ways BP shall be reduced? 





Eating Fish ……………………….! 
Any other specify  
   
16. Are you aware of adverse effects of HIGH Bp? If yes  
Heart attack 
Stroke 
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Bleeding in the brain 
Kidney failure 
Sub conjunctival hemorrhage 
Damage to blood vessels 
Any other specify  
17. For woman: During your pregnancy, did any one tell you 
that you have high B.P?  
   
18. Are you suffering from high BP even before pregnancy?    
19. For all: kindly give your opinion /views on high BP 
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